## metadata
source file: data/floodlamp/reg/fda-townhalls/dev-qa-extract/VTH 36_cemanual-sections.md
last updated: 2024-12-30 Created QA Sections
link pdf: https://www.fda.gov/media/144566/download?attachment
link youtube: https://youtu.be/VNrwrH0N0dY
link slides: 
topic: COVID-19
notes: delete and combine unimportant segments


## content

### qa


#### 1. Updates on COVID-19 Testing Developments and Priorities

QA Block 1-1
CLARIFIED QUESTION: What are the specific caveats about the use of pooling that test developers should be aware of?
CLARIFIED ANSWER: FDA advises test developers to review all caveats in the authorizations for pooling and note that authorized pooling for asymptomatic screening is specified. Off-label use is possible as long as specific limitations, like restricting use to symptomatic patients, are not applied.
VERBATIM QUESTION: What are the specific caveats about the use of pooling that test developers should be aware of?
VERBATIM ANSWER: Please note all the caveats in our authorizations about the use of pooling. And of course if the pooling scheme has not yet been authorized for an asymptomatic screening we do clearly state on the FDA Web site and we're supported by both the CDC and the CMS that you can use the tests that off label as long as there is no specific limitation about the use, very specific use limitations to very rare perhaps authorizations about the limitations to only symptomatic patients.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pooling guidelines, Test authorization, Off-label test use
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: Can tests be used off-label if they have no specific use limitations, and what constitutes a specific limitation on use?
CLARIFIED ANSWER: The FDA allows tests to be used off-label as long as there are no specific limitations on their use, such as authorizations restricting use to symptomatic patients.
VERBATIM QUESTION: Can tests be used off-label if they have no specific use limitations, and what constitutes a specific limitation on use?
VERBATIM ANSWER: And of course if the pooling scheme has not yet been authorized for an asymptomatic screening we do clearly state on the FDA Web site and we're supported by both the CDC and the CMS that you can use the tests that off label as long as there is no specific limitation about the use, very specific use limitations to very rare perhaps authorizations about the limitations to only symptomatic patients.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: off-label test use, specific use limitations
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: Are there any emerging data or guidelines supporting the use of panel tests for SARS-CoV-2 and flu detection?
CLARIFIED ANSWER: The FDA has authorized the first home collection panel test for SARS-CoV-2 and flu detection, signaling support for panel testing where supported by data.
VERBATIM QUESTION: Are there any emerging data or guidelines supporting the use of panel tests for SARS-CoV-2 and flu detection?
VERBATIM ANSWER: We also saw more home collection kits authorized and of note the first home collection for a panel test that involves both SARS-CoV-2 and flu detection. And of course we signal with that authorization our continued desire to see panel testing in all forms that are supported by data.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: panel tests, SARS-CoV-2 and flu detection, test authorization
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: What types of testing methodologies or formats does the FDA prioritize for SARS-CoV-2 diagnostics?
CLARIFIED ANSWER: The FDA prioritizes point-of-care tests, home collection kits, panel tests, and high-throughput systems for SARS-CoV-2 diagnostics to enable efficient testing of large sample volumes.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We - and want to remind everyone of our current highest priorities. This is - this - the priorities in two ways, one for review but also in seeking development of these tests from the development community. so that obviously they really haven't changed recently and so they are again point of care tests, home collection kits from home testing opportunities, panels and extremely high throughput systems that allow the most efficient testing of large volumes of samples.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA priorities, Testing methodologies, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: What does the FDA consider a high-throughput system for efficient testing of large sample volumes?
CLARIFIED ANSWER: FDA defines high-throughput systems as those enabling the most efficient testing of large sample volumes.
VERBATIM QUESTION: What does the FDA consider a high-throughput system for efficient testing of large sample volumes?
VERBATIM ANSWER: Extremely high throughput systems that allow the most efficient testing of large volumes of samples.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: high-throughput systems, large volume testing, FDA priorities
REVIEW FLAG: False


#### 2. Streamlining EUA Process for Open-Source LAMP-Based Assays

QA Block 2-1
CLARIFIED QUESTION: Can you provide guidance on the use of a consolidated primer set for a LAMP-based assay, specifically addressing inclusivity in silico analysis, in silico cross-reactivity, and wet cross-reactivity?
CLARIFIED ANSWER: FDA supports using consolidated primer sets as seen in models like Yale's SalivaDirect for open-source testing. Data on test performance can be leveraged via right of reference, either through individual EUA authorization or replication of an approved method. Changes in test components require review, but adherence to existing authorization setups reduces duplication and enhances efficiency.
VERBATIM QUESTION: Can you provide guidance on the use of a consolidated primer set for a LAMP-based assay, specifically addressing inclusivity in silico analysis, in silico cross-reactivity, and wet cross-reactivity?
VERBATIM ANSWER: Yes that's - we've seen that as a pathway that could be very successful. Of course the Yale saliva direct was the first to get authorization and we see a lot of interest in this sort of open source. As far as, you know, the data related to test performance yes that can be leveraged in a different - you know, in multiple ways. The two main ways are that if you seek your own authorization for the test you can give a right of reference for anyone else who wants to copy your test. That wouldn't eliminate the requirement for them to if they're a kit developer say for them to come in to get their own authorization. And it wouldn't extend the umbrella of an EUA authorization to any lab that might copy that method. So looking at the saliva direct model they have in their original submission and any amendments -- and I have to check what amendments they have to date -- they have an instruction for use that is the sole basis so to speak of the kit. And they point to off-the-shelf product that users can purchase. In the case of primers and probes for their tests - Toby you can correct me but I think it's the CDC's. And they can get that from vendors that produce primary probes under that CDC authorization. So those are very specific catalog numbers and those are primers and probes that we previously authorized. So again there's these two different pathways. I want to lay them out very clearly. You can get your own individual authorization for a kit. You can then give anybody, any other developer the right of reference to that and they can copy it and they can pretty much link up and use the data in your submission. There are some elements that if they were to be changed that we'd want to see. But if they are using the same suppliers for everything - and the same catalog numbers for everything that you're using then that makes it very easy. Or the other way is to have this method authorized as we did for saliva direct and then you - we would envision giving you or any other sponsors the same sort of flexibility that Yale is actually the one that designates which lab can use their method and are therefore covered by their EUA. And they have commitments to the FDA on what is required in making that determination of designation. And my understanding is they've designated quite a few labs already. And I would refer you to them if anybody wants to know those numbers but it appears to be a very highly successful program. So hopefully I've addressed the questions and...
SPEAKER QUESTION: Randy True (FloodLAMP PBC)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Consolidated primer sets, In silico and wet analysis, EUA authorization pathways
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: If we get authorization for a test using one type of activation buffer and purification method, and another developer pursues authorization with a different purification method but the same primer set and LAMP master mix, would they need to repeat the interfering substances testing?
CLARIFIED ANSWER: Additional validation may be required if changes are made to the test components. Developers can grant rights of reference, reducing duplication if core components remain the same.
VERBATIM QUESTION: If we get authorization for a test using one type of activation buffer and purification method, and another developer pursues authorization with a different purification method but the same primer set and LAMP master mix, would they need to repeat the interfering substances testing?
VERBATIM ANSWER: At a high level you're close. But the devil's sometimes in the detail. There are certain alterations to a test that we may require additional validation. So if they're adding something new that you didn't do say then we would want to evaluate the data around that change. And then you absolutely developers can give each other right of references as they so wish. They can specify what right they have or among their - from their entire EUA. They can have limitation or they can open them up entirely. But you can cross - basically cross reference each other's assays to the extent that you want. And there would absolutely be synergy. And if the components are all the same that they use for the core test then there would absolutely be synergy on reducing any sort of duplication that wouldn't - that isn't, you know, recommended because the tests are basically the same in those functions. Okay? So I look forward to hearing more about your development. Thank you so much.
SPEAKER QUESTION: Randy True (FloodLAMP PBC)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Test validation requirements, Rights of reference between developers, Reducing duplication in testing
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: If we provide another developer a general right of reference for our test, allowing them to get their own EUA and control their own designations, while we maintain our own separate EUA and designations, is that the correct process?
CLARIFIED ANSWER: Yes, developers can grant general rights of reference to others for separate EUAs, but changes to a test may require additional validation. Cross-referencing assays can reduce duplication if core components remain unchanged.
VERBATIM QUESTION: If we provide another developer a general right of reference for our test, allowing them to get their own EUA and control their own designations, while we maintain our own separate EUA and designations, is that the correct process?
VERBATIM ANSWER: At a high level you're close. But the devil's sometimes in the detail. There are certain alterations to a test that we may require additional validation. So if they're adding something new that you didn't do say then we would want to evaluate the data around that change. And then you absolutely developers can give each other right of references as they so wish. They can specify what right they have or among their - from their entire EUA. They can have limitation or they can open them up entirely. But you can cross - basically cross reference each other's assays to the extent that you want. And there would absolutely be synergy. And if the components are all the same that they use for the core test then there would absolutely be synergy on reducing any sort of duplication that wouldn't - that isn't, you know, recommended because the tests are basically the same in those functions.
SPEAKER QUESTION: Randy True (FloodLAMP PBC)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Right of reference, EUA process, Validation requirements
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: What are the specific criteria the FDA uses to determine when additional validation is required for alterations to an EUA authorized test?
CLARIFIED ANSWER: The FDA evaluates changes to a test to determine if they require additional validation. This includes assessing data for any new aspects not included in the original test. If components remain the same, duplication of validation can often be minimized.
VERBATIM QUESTION: What are the specific criteria the FDA uses to determine when additional validation is required for alterations to an EUA authorized test?
VERBATIM ANSWER: At a high level you're close. But the devil's sometimes in the detail. There are certain alterations to a test that we may require additional validation. So if they're adding something new that you didn't do say then we would want to evaluate the data around that change. And then you absolutely developers can give each other right of references as they so wish. They can specify what right they have or among their - from their entire EUA. They can have limitation or they can open them up entirely. But you can cross - basically cross reference each other's assays to the extent that you want. And there would absolutely be synergy. And if the components are all the same that they use for the core test then there would absolutely be synergy on reducing any sort of duplication that wouldn't - that isn't, you know, recommended because the tests are basically the same in those functions.
SPEAKER QUESTION: Randy True (FloodLAMP PBC)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA test alterations, FDA additional validation, developer collaboration
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: Does the use of a shared primer set with identical suppliers and catalog numbers eliminate the need for independent validations for each developer?
CLARIFIED ANSWER: Using the same suppliers and catalog numbers simplifies validation but does not entirely eliminate the need for independent evaluations.
VERBATIM QUESTION: Does the use of a shared primer set with identical suppliers and catalog numbers eliminate the need for independent validations for each developer?
VERBATIM ANSWER: But if they are using the same suppliers for everything - and the same catalog numbers for everything that you're using then that makes it very easy.
SPEAKER QUESTION: Randy True (FloodLAMP PBC)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: shared primer sets, validation requirements, EUA pathways
REVIEW FLAG: False

QA Block 2-6
CLARIFIED QUESTION: What commitments are required from developers in a model where they designate laboratories for use of their authorized test?
CLARIFIED ANSWER: Developers designating laboratories for their authorized test must meet FDA commitments for determining lab designations, as seen with the Yale SalivaDirect model.
VERBATIM QUESTION: What commitments are required from developers in a model where they designate laboratories for use of their authorized test?
VERBATIM ANSWER: Or the other way is to have this method authorized as we did for saliva direct and then you - we would envision giving you or any other sponsors the same sort of flexibility that Yale is actually the one that designates which lab can use their method and are therefore covered by their EUA. And they have commitments to the FDA on what is required in making that determination of designation. And my understanding is they've designated quite a few labs already.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Laboratory designation, FDA commitments, Test authorization
REVIEW FLAG: False

QA Block 2-7
CLARIFIED QUESTION: Under what circumstances would a developer opting for the saliva direct open-source model still need to perform new validations?
CLARIFIED ANSWER: Developers using the saliva direct open-source model must perform new validations if they make alterations to the test not included in the original EUA submission. Using identical components can reduce duplication.
VERBATIM QUESTION: Under what circumstances would a developer opting for the saliva direct open-source model still need to perform new validations?
VERBATIM ANSWER: At a high level you're close. But the devil's sometimes in the detail. There are certain alterations to a test that we may require additional validation. So if they're adding something new that you didn't do say then we would want to evaluate the data around that change. And then you absolutely developers can give each other right of references as they so wish. They can specify what right they have or among their - from their entire EUA. They can have limitation or they can open them up entirely. But you can cross - basically cross reference each other's assays to the extent that you want. And there would absolutely be synergy. And if the components are all the same that they use for the core test then there would absolutely be synergy on reducing any sort of duplication that wouldn't - that isn't, you know, recommended because the tests are basically the same in those functions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva direct model, validation requirements, test alterations
REVIEW FLAG: False

QA Block 2-8
CLARIFIED QUESTION: Can the FDA clarify the flexibility extended to developers adopting a model similar to the Yale saliva direct approach?
CLARIFIED ANSWER: The FDA sees the Yale saliva direct model as a successful, flexible approach for test developers. Developers can seek their own authorization and grant authorization references for others to use. Alternatively, like saliva direct, methods can be authorized with a mechanism that allows sponsors to designate labs covered under their EUA, while ensuring compliance with FDA requirements.
VERBATIM QUESTION: Can the FDA clarify the flexibility extended to developers adopting a model similar to the Yale saliva direct approach?
VERBATIM ANSWER: Yes that's - we've seen that as a pathway that could be very successful. Of course the Yale saliva direct was the first to get authorization and we see a lot of interest in this sort of open source. As far as, you know, the data related to test performance yes that can be leveraged in a different - you know, in multiple ways. The two main ways are that if you seek your own authorization for the test you can give a right of reference for anyone else who wants to copy your test. That wouldn't eliminate the requirement for them to if they're a kit developer say for them to come in to get their own authorization. And it wouldn't extend the umbrella of an EUA authorization to any lab that might copy that method. So looking at the saliva direct model they have in their original submission and any amendments -- and I have to check what amendments they have to date -- they have an instruction for use that is the sole basis so to speak of the kit. And they point to off-the-shelf product that users can purchase. In the case of primers and probes for their tests - Toby you can correct me but I think it's the CDC's. And they can get that from vendors that produce primary probes under that CDC authorization. So those are very specific catalog numbers and those are primers and probes that we previously authorized. So again there's these two different pathways. I want to lay them out very clearly. You can get your own individual authorization for a kit. You can then give anybody, any other developer the right of reference to that and they can copy it and they can pretty much link up and use the data in your submission. There are some elements that if they were to be changed that we'd want to see. But if they are using the same suppliers for everything - and the same catalog numbers for everything that you're using then that makes it very easy. Or the other way is to have this method authorized as we did for saliva direct and then you - we would envision giving you or any other sponsors the same sort of flexibility that Yale is actually the one that designates which lab can use their method and are therefore covered by their EUA. And they have commitments to the FDA on what is required in making that determination of designation. And my understanding is they've designated quite a few labs already. And I would refer you to them if anybody wants to know those numbers but it appears to be a very highly successful program.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Yale saliva direct model, Test developer flexibility, EUA processes
REVIEW FLAG: False

QA Block 2-9
CLARIFIED QUESTION: What processes do developers need to follow to give specific or limited rights of reference to another developer?
CLARIFIED ANSWER: Developers can provide other developers with rights of reference for their EUA, specifying whether these rights are limited or full. Such cross-referencing reduces duplication if the tests use identical components.
VERBATIM QUESTION: What processes do developers need to follow to give specific or limited rights of reference to another developer?
VERBATIM ANSWER: And then you absolutely developers can give each other right of references as they so wish. They can specify what right they have or among their - from their entire EUA. They can have limitation or they can open them up entirely. But you can cross - basically cross reference each other's assays to the extent that you want. And there would absolutely be synergy. And if the components are all the same that they use for the core test then there would absolutely be synergy on reducing any sort of duplication that wouldn't - that isn't, you know, recommended because the tests are basically the same in those functions.
SPEAKER QUESTION: Randy True (FloodLAMP PBC)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Rights of reference, EUA cross-referencing, Test validation
REVIEW FLAG: False

QA Block 2-10
CLARIFIED QUESTION: What elements of a test's core components are necessary to remain unchanged to reduce duplication of validation efforts?
CLARIFIED ANSWER: To reduce duplication of validation efforts, test developers should use the same suppliers and catalog numbers for all core components.
VERBATIM QUESTION: What elements of a test's core components are necessary to remain unchanged to reduce duplication of validation efforts?
VERBATIM ANSWER: There are some elements that if they were to be changed that we'd want to see. But if they are using the same suppliers for everything - and the same catalog numbers for everything that you're using then that makes it very easy.
SPEAKER QUESTION: Randy True (FloodLAMP PBC)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation duplication, Core test components, Test suppliers
REVIEW FLAG: False


#### 3. Point-of-Care Use of Antibody Test Kits

QA Block 3-1
CLARIFIED QUESTION: Does the FDA agree that point-of-care facilities can use both fingerstick and venous draw whole blood but not plasma and serum for antibody test kits authorized for point-of-care use?
CLARIFIED ANSWER: Yes, point-of-care facilities can use both fingerstick and venous draw whole blood for antibody test kits authorized for such use, but not plasma or serum due to the training and equipment requirements.
VERBATIM QUESTION: Does the FDA agree that point-of-care facilities can use both fingerstick and venous draw whole blood but not plasma and serum for antibody test kits authorized for point-of-care use?
VERBATIM ANSWER: That would be correct. There are point-of-care assays. Obviously say physician offices can draw a whole blood, and those offices are permitted to use whole blood in a point-of-care assay, yes absolutely. Yes it's a little - to add a synergy step for plasma or serum that would be in all likelihood something different. Although there are developers who are going to look at, you know, devices that might be able to use point-of-care but in general they're not - these facilities are not trained in using nitro fuses and maintaining them okay? So hopefully that clarifies that.
SPEAKER QUESTION: Shannon Clark (UserWise Consulting)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: point-of-care facilities, antibody test kits, specimen types
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: Can devices designed to use plasma or serum be adapted for point-of-care use?
CLARIFIED ANSWER: Devices using plasma or serum would require additional steps and are generally not suited for point-of-care because such facilities are not equipped to handle these processes.
VERBATIM QUESTION: Can devices designed to use plasma or serum be adapted for point-of-care use?
VERBATIM ANSWER: Yes it's a little - to add a synergy step for plasma or serum that would be in all likelihood something different. Although there are developers who are going to look at, you know, devices that might be able to use point-of-care but in general they're not - these facilities are not trained in using nitro fuses and maintaining them okay?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: plasma/serum adaptation, point-of-care diagnostics
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: What are the training requirements or limitations for point-of-care facilities when handling specific types of diagnostic specimens?
CLARIFIED ANSWER: Point-of-care facilities, such as physician offices, can use whole blood for assays but are not trained or equipped to handle plasma or serum, which require additional technical steps like centrifugation.
VERBATIM QUESTION: What are the training requirements or limitations for point-of-care facilities when handling specific types of diagnostic specimens?
VERBATIM ANSWER: There are point-of-care assays. Obviously say physician offices can draw a whole blood, and those offices are permitted to use whole blood in a point-of-care assay, yes absolutely. Yes it's a little - to add a synergy step for plasma or serum that would be in all likelihood something different. Although there are developers who are going to look at, you know, devices that might be able to use point-of-care but in general they're not - these facilities are not trained in using nitro fuses and maintaining them okay? So hopefully that clarifies that.
SPEAKER QUESTION: Shannon Clark (UserWise Consulting)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: point-of-care training, specimen handling, diagnostic assay limitations
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: Are there any restrictions on point-of-care facilities using certain types of blood specimens like venous draw whole blood?
CLARIFIED ANSWER: FDA confirms that point-of-care facilities can use both fingerstick and venous draw whole blood specimens, but not plasma or serum, due to additional complexity associated with those specimens.
VERBATIM QUESTION: Are there any restrictions on point-of-care facilities using certain types of blood specimens like venous draw whole blood?
VERBATIM ANSWER: That would be correct. There are point-of-care assays. Obviously say physician offices can draw a whole blood, and those offices are permitted to use whole blood in a point-of-care assay, yes absolutely. Yes it's a little - to add a synergy step for plasma or serum that would be in all likelihood something different. Although there are developers who are going to look at, you know, devices that might be able to use point-of-care but in general they're not - these facilities are not trained in using nitro fuses and maintaining them okay? So hopefully that clarifies that.
SPEAKER QUESTION: Shannon Clark (UserWise Consulting)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point-of-care blood specimen use, Venous draw whole blood, Plasma and serum restrictions
REVIEW FLAG: False


#### 4. Requirements for Retrospective Studies and Fresh Sample Testing

QA Block 4-2
CLARIFIED QUESTION: Do you still recommend five fresh samples for retrospective studies if dry fresh swabs, not in VTM but frozen, are used?
CLARIFIED ANSWER: The FDA recommends using five fresh samples for retrospective studies as the device is intended to be used without freezing the swabs. Fresh sample studies can be completed post-market if authorization criteria are met. Freezing swabs may alter assay performance by making more target available.
VERBATIM QUESTION: Do you still recommend five fresh samples for retrospective studies if dry fresh swabs, not in VTM but frozen, are used?
VERBATIM ANSWER: Well the challenge is on that last question if you freeze the swabs then we've only evaluated data premarket on frozen swabs. And then we wouldn't wanted to require users to freeze those swabs. Most point-of-care sites don't have freezers to do that and obviously it would be very impractical. So yes we are recommending a minimum of five positives of fresh samples as the device is intended to be used. And we are providing a huge amount of flexibility in allowing the completion of the fresh sample studies post market if everything up to that point where we can make authorization decisions looks good. So hopefully that explains our thinking around that. For example, I'll just go a bit further. We have seen some potential evidence that freeze thaw may make more target available for some assays. And so that could actually improve your performance due to a freeze.
SPEAKER QUESTION: Wendy Strongen
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: retrospective studies, fresh versus frozen samples, freezer requirements for swabs
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: Does the FDA allow flexibility for completing fresh sample studies for retrospective studies post-market?
CLARIFIED ANSWER: The FDA allows flexibility for completing fresh sample studies post-market if the data supports authorization, and recommends a minimum of five positive fresh samples as intended for use.
VERBATIM QUESTION: Does the FDA allow flexibility for completing fresh sample studies for retrospective studies post-market?
VERBATIM ANSWER: So yes we are recommending a minimum of five positives of fresh samples as the device is intended to be used. And we are providing a huge amount of flexibility in allowing the completion of the fresh sample studies post market if everything up to that point where we can make authorization decisions looks good.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: post-market studies, fresh sample tests, FDA flexibility
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: Does the freeze-thaw process of swabs affect assay performance or target availability in a way that impacts study design or results?
CLARIFIED ANSWER: FDA has observed potential evidence that freeze-thaw may increase target availability for some assays, potentially improving performance.
VERBATIM QUESTION: Does the freeze-thaw process of swabs affect assay performance or target availability in a way that impacts study design or results?
VERBATIM ANSWER: We have seen some potential evidence that freeze thaw may make more target available for some assays. And so that could actually improve your performance due to a freeze.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: freeze-thaw impact, assay performance, target availability
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: Why is it considered impractical to require freezing swabs for point-of-care sites?
CLARIFIED ANSWER: Requiring freezing swabs for point-of-care sites is impractical because most of these sites lack freezers.
VERBATIM QUESTION: Why is it considered impractical to require freezing swabs for point-of-care sites?
VERBATIM ANSWER: Most point-of-care sites don't have freezers to do that and obviously it would be very impractical.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: freezing swabs, point-of-care-site logistics, rapid antigen tests
REVIEW FLAG: False


#### 5. Over-the-Counter COVID-19 Testing Developments and Validation Standards

QA Block 5-1
CLARIFIED QUESTION: Do you have information about tests mentioned by President Trump that don't require doctors to administer the test?
CLARIFIED ANSWER: The FDA has provided recommendations for validating over-the-counter COVID-19 tests but has not yet authorized any. The FDA is open to non-prescription tests but requires higher performance standards when healthcare professionals are not involved.
VERBATIM QUESTION: Do you have information about tests mentioned by President Trump that don't require doctors to administer the test?
VERBATIM ANSWER: So just on this, you know, something that I've been highlighting on calls and other situations and we've provided so-called OTC over-the-counter or direct to consumer recommendations for validation. To my knowledge we have not authorized one, although I have to check always on everything minute to minute. But we're entirely open to a SARS-test, a COVID test that does not require a prescription. And so I want to thank you for the opportunity to reiterate that. We do - if you look at our template, require a little bit higher performance when a physician or a clinician, a healthcare worker is not involved in the loop on testing. And that's because the consumer, the patient at home don't have the benefit of running the test results by their clinician to make sure that they are making the best possible interpretation of the findings and how it impacts their health or other people's health. So thank you again for that question.
SPEAKER QUESTION: Griffin Soriano (William Blair)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Over-the-counter COVID-19 tests, Non-prescription COVID tests, Test validation requirements
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: Are these tests that don't involve healthcare professionals similar to the ones we already have or are they true over-the-counter tests for COVID-19?
CLARIFIED ANSWER: The FDA has provided validation recommendations for over-the-counter or direct-to-consumer COVID-19 tests but hasn't authorized any yet. They are open to approving tests that don't require a prescription, but these need higher performance standards since healthcare professionals are not involved in interpreting results.
VERBATIM QUESTION: Are these tests that don't involve healthcare professionals similar to the ones we already have or are they true over-the-counter tests for COVID-19?
VERBATIM ANSWER: So just on this, you know, something that I've been highlighting on calls and other situations and we've provided so-called OTC over-the-counter or direct to consumer recommendations for validation. To my knowledge we have not authorized one, although I have to check always on everything minute to minute. But we're entirely open to a SARS-test, a COVID test that does not require a prescription. And so I want to thank you for the opportunity to reiterate that. We do - if you look at our template, require a little bit higher performance when a physician or a clinician, a healthcare worker is not involved in the loop on testing. And that's because the consumer, the patient at home don't have the benefit of running the test results by their clinician to make sure that they are making the best possible interpretation of the findings and how it impacts their health or other people's health.
SPEAKER QUESTION: Griffin Soriano (William Blair)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Over-the-counter COVID-19 tests, FDA test authorization, Test performance standards
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: What are the FDA's validation recommendations for over-the-counter or direct-to-consumer COVID-19 tests?
CLARIFIED ANSWER: The FDA has provided validation recommendations for over-the-counter or direct-to-consumer COVID-19 tests, requiring higher performance standards due to the lack of healthcare workers in the testing process. No such test has yet been authorized.
VERBATIM QUESTION: What are the FDA's validation recommendations for over-the-counter or direct-to-consumer COVID-19 tests?
VERBATIM ANSWER: So just on this, you know, something that I've been highlighting on calls and other situations and we've provided so-called OTC over-the-counter or direct to consumer recommendations for validation. To my knowledge we have not authorized one, although I have to check always on everything minute to minute. But we're entirely open to a SARS-test, a COVID test that does not require a prescription. And so I want to thank you for the opportunity to reiterate that. We do - if you look at our template, require a little bit higher performance when a physician or a clinician, a healthcare worker is not involved in the loop on testing. And that's because the consumer, the patient at home don't have the benefit of running the test results by their clinician to make sure that they are making the best possible interpretation of the findings and how it impacts their health or other people's health.
SPEAKER QUESTION: Griffin Soriano (William Blair)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation criteria for OTC COVID-19 tests, COVID-19 test authorization, Home testing considerations
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: Are there currently any FDA authorizations for COVID-19 diagnostic tests that do not require a prescription?
CLARIFIED ANSWER: Currently, the FDA has not authorized any COVID-19 diagnostic tests that do not require a prescription, but it is open to authorizing them if they meet higher performance criteria.
VERBATIM QUESTION: Are there currently any FDA authorizations for COVID-19 diagnostic tests that do not require a prescription?
VERBATIM ANSWER: To my knowledge we have not authorized one, although I have to check always on everything minute to minute. But we're entirely open to a SARS-test, a COVID test that does not require a prescription. And so I want to thank you for the opportunity to reiterate that. We do - if you look at our template, require a little bit higher performance when a physician or a clinician, a healthcare worker is not involved in the loop on testing. And that's because the consumer, the patient at home don't have the benefit of running the test results by their clinician to make sure that they are making the best possible interpretation of the findings and how it impacts their health or other people's health.
SPEAKER QUESTION: Griffin Soriano (William Blair)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Over-the-counter COVID-19 tests, FDA authorization criteria, Prescription-free diagnostics
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: Why does the FDA set higher performance requirements for tests not involving healthcare professionals?
CLARIFIED ANSWER: The FDA requires higher performance for tests not involving healthcare professionals to ensure patients can accurately interpret results without a clinician's guidance.
VERBATIM QUESTION: Why does the FDA set higher performance requirements for tests not involving healthcare professionals?
VERBATIM ANSWER: We do - if you look at our template, require a little bit higher performance when a physician or a clinician, a healthcare worker is not involved in the loop on testing. And that's because the consumer, the patient at home don't have the benefit of running the test results by their clinician to make sure that they are making the best possible interpretation of the findings and how it impacts their health or other people's health.
SPEAKER QUESTION: Griffin Soriano (William Blair)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Higher performance requirements, Tests without healthcare professionals, Patient safety
REVIEW FLAG: False


#### 6. AI Software Validation Requirements for COVID-19 Assays

QA Block 6-1
CLARIFIED QUESTION: What extent of software validation is required for a support vector machine used in COVID-19 assay classification?
CLARIFIED ANSWER: The FDA expects less extensive software documentation for EUAs compared to full authorizations, focusing on the critical components and ensuring no obvious errors that could lead to false results. Specific requirements depend on the software's use case, and developers should engage with the FDA early.
VERBATIM QUESTION: What extent of software validation is required for a support vector machine used in COVID-19 assay classification?
VERBATIM ANSWER: Okay no that's okay. I will attempt to answer in general. So for EUAs whenever software is involved they are typically not asking for the extensive software documentation that we would for a full authorization. And we instead want developers to focus on the most critical components prior to authorization. And that will somewhat be in dialogue with the review staff when they know about the details. And so that is - our intent is to at launch have no obvious errors in the software that can lead to false or inaccurate results. So it is going to be a much lower bar for EUAs. And exactly what that - the recommendations are from the FDA is somewhat dependent on the exact software and it's intended use and its point acquired use. So thanks for the question. I think it's, you know, important then to not to necessarily delay a submission and go overboard on software validation but engage early and often or at least early with the FDA on your particular device. Thank you.
SPEAKER QUESTION: Christie Bergerson (Exponent)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: software validation, COVID-19 diagnostics, EUA requirements
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: Does the FDA require typical co-documentation for software validation, such as testing analysis, requirement specifications, design specifications, and the full validation suite?
CLARIFIED ANSWER: For EUAs, the FDA does not require extensive software documentation typically required for full authorization. Developers should focus on critical components and consult with FDA review staff for specific recommendations.
VERBATIM QUESTION: Does the FDA require typical co-documentation for software validation, such as testing analysis, requirement specifications, design specifications, and the full validation suite?
VERBATIM ANSWER: So for EUAs whenever software is involved they are typically not asking for the extensive software documentation that we would for a full authorization. And we instead want developers to focus on the most critical components prior to authorization. And that will somewhat be in dialogue with the review staff when they know about the details. And so that is - our intent is to at launch have no obvious errors in the software that can lead to false or inaccurate results. So it is going to be a much lower bar for EUAs. And exactly what that - the recommendations are from the FDA is somewhat dependent on the exact software and it's intended use and its point acquired use.
SPEAKER QUESTION: Christie Bergerson (Exponent)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA software validation, Documentation requirements, FDA recommendations
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: If each end user calibrates the AI algorithm to their instrument, should the calibration set be included in a change plan like a software as a medical device pre-specification or algorithm change protocols?
CLARIFIED ANSWER: For EUAs, FDA does not require extensive software documentation like a full authorization. Developers should focus on critical components, aiming to ensure no obvious software errors that lead to inaccurate results. The exact requirements depend on the intended use and type of software.
VERBATIM QUESTION: If each end user calibrates the AI algorithm to their instrument, should the calibration set be included in a change plan like a software as a medical device pre-specification or algorithm change protocols?
VERBATIM ANSWER: Okay no that's okay. I will attempt to answer in general. So for EUAs whenever software is involved they are typically not asking for the extensive software documentation that we would for a full authorization. And we instead want developers to focus on the most critical components prior to authorization. And that will somewhat be in dialogue with the review staff when they know about the details. And so that is - our intent is to at launch have no obvious errors in the software that can lead to false or inaccurate results. So it is going to be a much lower bar for EUAs. And exactly what that - the recommendations are from the FDA is somewhat dependent on the exact software and it's intended use and its point acquired use.
SPEAKER QUESTION: Christie Bergerson (Exponent)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA software calibration, AI algorithm requirements, Software validation guidelines
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: How in-depth is the software validation expected to be, given the molecular template states the software should be validated as free of defects but acknowledges no software can truly be free of defects?
CLARIFIED ANSWER: For EUAs, the FDA requires less extensive software documentation than for full authorizations. Developers should focus on addressing critical components to avoid errors that could lead to inaccurate results, and recommendations depend on software details and intended use. Early engagement with the FDA is encouraged.
VERBATIM QUESTION: How in-depth is the software validation expected to be, given the molecular template states the software should be validated as free of defects but acknowledges no software can truly be free of defects?
VERBATIM ANSWER: So for EUAs whenever software is involved they are typically not asking for the extensive software documentation that we would for a full authorization. And we instead want developers to focus on the most critical components prior to authorization. And that will somewhat be in dialogue with the review staff when they know about the details. And so that is - our intent is to at launch have no obvious errors in the software that can lead to false or inaccurate results. So it is going to be a much lower bar for EUAs. And exactly what that - the recommendations are from the FDA is somewhat dependent on the exact software and it's intended use and its point acquired use. So thanks for the question. I think it's, you know, important then to not to necessarily delay a submission and go overboard on software validation but engage early and often or at least early with the FDA on your particular device.
SPEAKER QUESTION: Christie Bergerson (Exponent)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA software validation, Critical software components, FDA submission process
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: Does the FDA recommend differing levels of software documentation for EUA submissions compared to full authorizations?
CLARIFIED ANSWER: The FDA requires less extensive software documentation for EUAs compared to full authorizations, focusing on critical components to avoid obvious errors. Specific recommendations depend on the software's intended use and context.
VERBATIM QUESTION: Does the FDA recommend differing levels of software documentation for EUA submissions compared to full authorizations?
VERBATIM ANSWER: So for EUAs whenever software is involved they are typically not asking for the extensive software documentation that we would for a full authorization. And we instead want developers to focus on the most critical components prior to authorization. And that will somewhat be in dialogue with the review staff when they know about the details. And so that is - our intent is to at launch have no obvious errors in the software that can lead to false or inaccurate results. So it is going to be a much lower bar for EUAs. And exactly what that - the recommendations are from the FDA is somewhat dependent on the exact software and it's intended use and its point acquired use.
SPEAKER QUESTION: Christie Bergerson (Exponent)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA software validation, Full authorization software requirements, FDA guidance
REVIEW FLAG: False

QA Block 6-6
CLARIFIED QUESTION: What constitutes the most critical software components that should be focused on prior to EUA authorization for COVID-19 assays?
CLARIFIED ANSWER: The critical software components to focus on for EUAs are those ensuring no obvious errors in the software that could result in false or inaccurate results. The requirements are less extensive than those for full authorization and should involve early and open communication with the FDA to address device-specific needs.
VERBATIM QUESTION: What constitutes the most critical software components that should be focused on prior to EUA authorization for COVID-19 assays?
VERBATIM ANSWER: Okay no that's okay. I will attempt to answer in general. So for EUAs whenever software is involved they are typically not asking for the extensive software documentation that we would for a full authorization. And we instead want developers to focus on the most critical components prior to authorization. And that will somewhat be in dialogue with the review staff when they know about the details. And so that is - our intent is to at launch have no obvious errors in the software that can lead to false or inaccurate results. So it is going to be a much lower bar for EUAs. And exactly what that - the recommendations are from the FDA is somewhat dependent on the exact software and it's intended use and its point acquired use. So thanks for the question. I think it's, you know, important then to not to necessarily delay a submission and go overboard on software validation but engage early and often or at least early with the FDA on your particular device. Thank you.
SPEAKER QUESTION: Christie Bergerson (Exponent)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: critical software components, EUA requirements, software validation guidance
REVIEW FLAG: False

QA Block 6-7
CLARIFIED QUESTION: How does the intended use or point-of-care setting influence the FDA's software validation recommendations for diagnostic devices?
CLARIFIED ANSWER: The FDA's software validation recommendations depend on the software's intended use and its point-of-care setting. For EUAs, the FDA generally requires less extensive documentation, focusing on critical components and avoiding obvious errors rather than full validation.
VERBATIM QUESTION: How does the intended use or point-of-care setting influence the FDA's software validation recommendations for diagnostic devices?
VERBATIM ANSWER: Okay no that's okay. I will attempt to answer in general. So for EUAs whenever software is involved they are typically not asking for the extensive software documentation that we would for a full authorization. And we instead want developers to focus on the most critical components prior to authorization. And that will somewhat be in dialogue with the review staff when they know about the details. And so that is - our intent is to at launch have no obvious errors in the software that can lead to false or inaccurate results. So it is going to be a much lower bar for EUAs. And exactly what that - the recommendations are from the FDA is somewhat dependent on the exact software and it's intended use and its point acquired use.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA software validation, point-of-care use, FDA recommendations
REVIEW FLAG: False

QA Block 6-8
CLARIFIED QUESTION: Does engaging in early communication with the FDA reduce the chances of delays caused by over-preparing documentation?
CLARIFIED ANSWER: Engaging early with the FDA can help avoid over-preparation of software validation documentation for EUAs, as only the most critical components are typically required before authorization. The process depends on the software's intended use.
VERBATIM QUESTION: Does engaging in early communication with the FDA reduce the chances of delays caused by over-preparing documentation?
VERBATIM ANSWER: So for EUAs whenever software is involved they are typically not asking for the extensive software documentation that we would for a full authorization. And we instead want developers to focus on the most critical components prior to authorization. And that will somewhat be in dialogue with the review staff when they know about the details. And so that is - our intent is to at launch have no obvious errors in the software that can lead to false or inaccurate results. So it is going to be a much lower bar for EUAs. And exactly what that - the recommendations are from the FDA is somewhat dependent on the exact software and it's intended use and its point acquired use. So thanks for the question. I think it's, you know, important then to not to necessarily delay a submission and go overboard on software validation but engage early and often or at least early with the FDA on your particular device.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: early communication, FDA EUA process, software validation
REVIEW FLAG: False


#### 7. Regulatory Requirements for Saliva Collection Device Authorization

QA Block 7-1
CLARIFIED QUESTION: Is registration of the saliva collection device with the FDA sufficient to use it with any EUA-approved saliva tests?
CLARIFIED ANSWER: No, registering a saliva collection device with the FDA is not sufficient. Devices for RNA preservation typically require FDA authorization, and any device making claims for saliva collection for SARS-CoV-2 would require FDA review.
VERBATIM QUESTION: Is registration of the saliva collection device with the FDA sufficient to use it with any EUA-approved saliva tests?
VERBATIM ANSWER: The best short answer is to say no but to provide some more color to that. And Toby is this something that you want to handle today an area that you've been focusing on or you Crosstalk [...] Yes I think I didn't fully follow the question. But if you're asking whether you only need to register and list or whether there are other requirements, there generally are other requirements especially for saliva collection devices for RNA preservation. Those typically do need FDA authorization either in the form of clearance or approval or an EUA. [...] And it goes beyond just preservation any claim about saliva for our SARS-CoV-2 would for someone who manufacturer's collection kit and distributes it would require a review by the FDA.
SPEAKER QUESTION: Susan Sharp
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA registration, Saliva collection devices, EUA requirements
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: __If a saliva collection device is an empty tube__ with no preservatives or coatings, does it require FDA authorization?
CLARIFIED ANSWER: If a test developer uses an empty sterile tube and does not make claims about RNA preservation, they assume responsibility. However, manufacturers marketing such tubes for saliva collection with RNA preservation must demonstrate performance and comply with regulatory requirements.
VERBATIM QUESTION: If a saliva collection device is an empty tube with no preservatives or coatings, does it require FDA authorization?
VERBATIM ANSWER: So if you're - if you are a test developer and you're including in your test instructions that sample collection is done with an empty tube, just a commercially available sterile tube that is not made - the tube is not making any claims or the developer of the tube is not making any claims about RNA preservation then you as the test developer would be taking responsibility for that being a component of your test. On the other hand if you are a manufacturer of sterile tubes and you want to market those sterile tubes for saliva collection with RNA preservation even if it is a completely empty tube, then we would expect to see some performance demonstrated with a representative assay. And we would expect that tube to follow the regulatory requirements for an RNA preservation saliva collection device.
SPEAKER QUESTION: Susan Sharp
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Saliva collection devices, FDA authorization, RNA preservation
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: What requirements apply if a test developer includes a commercially available sterile tube, with no RNA preservation claims, as part of their test?
CLARIFIED ANSWER: If a test developer uses a commercially available sterile tube with no RNA preservation claims as part of their test, they are responsible for ensuring its suitability. Manufacturers marketing tubes for RNA preservation must meet regulatory requirements, including demonstrating performance.
VERBATIM QUESTION: What requirements apply if a test developer includes a commercially available sterile tube, with no RNA preservation claims, as part of their test?
VERBATIM ANSWER: So if you're - if you are a test developer and you're including in your test instructions that sample collection is done with an empty tube, just a commercially available sterile tube that is not made - the tube is not making any claims or the developer of the tube is not making any claims about RNA preservation then you as the test developer would be taking responsibility for that being a component of your test. On the other hand if you are a manufacturer of sterile tubes and you want to market those sterile tubes for saliva collection with RNA preservation even if it is a completely empty tube, then we would expect to see some performance demonstrated with a representative assay. And we would expect that tube to follow the regulatory requirements for an RNA preservation saliva collection device.
SPEAKER QUESTION: Susan Sharp
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: test developer responsibilities, sterile tube requirements, RNA preservation
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: What are the performance demonstration requirements for an empty sterile tube a manufacturer markets for RNA preservation?
CLARIFIED ANSWER: A manufacturer marketing an empty sterile tube for RNA preservation must demonstrate performance with a representative assay and follow regulatory requirements for RNA preservation devices.
VERBATIM QUESTION: What are the performance demonstration requirements for an empty sterile tube a manufacturer markets for RNA preservation?
VERBATIM ANSWER: So if you're - if you are a test developer and you're including in your test instructions that sample collection is done with an empty tube, just a commercially available sterile tube that is not made - the tube is not making any claims or the developer of the tube is not making any claims about RNA preservation then you as the test developer would be taking responsibility for that being a component of your test. On the other hand if you are a manufacturer of sterile tubes and you want to market those sterile tubes for saliva collection with RNA preservation even if it is a completely empty tube, then we would expect to see some performance demonstrated with a representative assay. And we would expect that tube to follow the regulatory requirements for an RNA preservation saliva collection device.
SPEAKER QUESTION: Susan Sharp
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Performance requirements for sterile tubes, Regulatory requirements, RNA preservation
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: Do devices marketed for RNA preservation, regardless of explicit SARS-CoV-2 claims, still require FDA authorization?
CLARIFIED ANSWER: FDA authorizations are required for all saliva collection devices making RNA preservation claims, even if unrelated to SARS-CoV-2.
VERBATIM QUESTION: Do devices marketed for RNA preservation, regardless of explicit SARS-CoV-2 claims, still require FDA authorization?
VERBATIM ANSWER: And I think I made a comment on the call last week indicating that, you know, making it clear that that if you're making claims about SARS-CoV-2 that you would be need to have authorization. And I think there was some confusion that if you're not making claims specifically about SARS-CoV-2 that you wouldn't - but that's not actually that was not the point that I was trying to make I think I was not very clear because even if you are just making RNA, you know, just saliva collection device claim not tied to SARS-CoV-2 you'd also still have regulatory requirements.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: RNA preservation, FDA authorization, Saliva collection devices
REVIEW FLAG: False

QA Block 7-6
CLARIFIED QUESTION: Is FDA review required for any device that makes claims about saliva collection for SARS-CoV-2 testing?
CLARIFIED ANSWER: Yes, FDA review is required for any saliva collection device making claims about SARS-CoV-2 testing.
VERBATIM QUESTION: Is FDA review required for any device that makes claims about saliva collection for SARS-CoV-2 testing?
VERBATIM ANSWER: And it goes beyond just preservation any claim about saliva for our SARS-CoV-2 would for someone who manufacturer's collection kit and distributes it would require a review by the FDA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA review, saliva collection devices, SARS-CoV-2 testing
REVIEW FLAG: False


#### 8. Key Requirements for OTC and Multiplex Test Authorization

QA Block 8-1
CLARIFIED QUESTION: What is the performance feature required to obtain an OTC non-prescribed indication versus an Rx non-lab use claimed indication?
CLARIFIED ANSWER: FDA clarified that the required performance feature for OTC authorization is not solely related to the 99% NPA for asymptomatic subjects. Recommendations in templates are not absolute requirements, and they consider mitigations like labeling and training to allow lower specificity.
VERBATIM QUESTION: What is the performance feature required to obtain an OTC non-prescribed indication versus an Rx non-lab use claimed indication?
VERBATIM ANSWER: So that's an important question. The short answer is no. The, you know, template recommendations are just that, recommendations. On specificity of the home test we would entertain a lower specificity depending on other mitigations which maybe labeling and training -- things like that. So is not again the recommendations and templates are just that and it is not something that is holding up authorization of any OTC devices.
SPEAKER QUESTION: Lubna
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC versus RX test indications, Performance requirements, FDA templates
REVIEW FLAG: False

QA Block 8-2
CLARIFIED QUESTION: Is the asymptomatic subject NPA of 99% the reason that current non-lab use tests are prescription use only?
CLARIFIED ANSWER: No, the asymptomatic subject NPA of 99% is not the reason why non-lab use tests are prescription-only. FDA is open to lower specificities with appropriate mitigations like labeling and training. This is not holding up OTC authorizations.
VERBATIM QUESTION: Is the asymptomatic subject NPA of 99% the reason that current non-lab use tests are prescription use only?
VERBATIM ANSWER: So that's an important question. The short answer is no. The, you know, template recommendations are just that, recommendations. On specificity of the home test we would entertain a lower specificity depending on other mitigations which maybe labeling and training -- things like that. So is not again the recommendations and templates are just that and it is not something that is holding up authorization of any OTC devices.
SPEAKER QUESTION: Lubna
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC non-prescription test requirements, NPA performance metric, Specificity in test authorization
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: Is the asymptomatic subject NPA of 99% the key performance discriminator holding up true OTC authorization?
CLARIFIED ANSWER: No, the asymptomatic subject NPA of 99% is not holding up OTC authorization. FDA is open to lower specificity with appropriate mitigations such as labeling and training.
VERBATIM QUESTION: Is the asymptomatic subject NPA of 99% the key performance discriminator holding up true OTC authorization?
VERBATIM ANSWER: So that's an important question. The short answer is no. The, you know, template recommendations are just that, recommendations. On specificity of the home test we would entertain a lower specificity depending on other mitigations which maybe labeling and training -- things like that. So is not again the recommendations and templates are just that and it is not something that is holding up authorization of any OTC devices.
SPEAKER QUESTION: Lubna
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC test authorization, Specificity requirements, FDA recommendations
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: Are you open to receiving a test that is not an already cleared multiplex test that includes multiple analytes like SARS-CoV-2 and RSV for EUA authorization?
CLARIFIED ANSWER: FDA is open to new multiplex panels not previously cleared, provided they include SARS-CoV-2. Additional data on non-SARS-CoV-2 targets may be required, and post-market commitments might ensure full authorization alignment.
VERBATIM QUESTION: Are you open to receiving a test that is not an already cleared multiplex test that includes multiple analytes like SARS-CoV-2 and RSV for EUA authorization?
VERBATIM ANSWER: You're about 50% right. First of all absolutely we are welcoming any new panels that haven't been seen by us before as long as they have SARS-CoV-2 on it. We - because they're say for flu or RSV, there are current full authorized tests for those targets. We are asking for somebody who has not already gotten a panel authorized by the FDA, full authorization by the FDA and then they're adding SARS-CoV-2 to it, if someone's coming with an entirely new panel, maybe they're adding a panel to their previous SARS-CoV-2 test EUA, we want to see a little bit more data about those non-SARS-CoV-2 targets. And typically it has been the case where we have post-market commitments after EUA authorization to do additional studies on those target - on those non-SARS-CoV-2 targets in order to bring it up more in line with full authorization and enable an easier full authorization of those panels. So we want to provide assurances to everyone that the targets are working for those that have other full authorization. At the same time we want to make - be as least burdensome as possible and at least in the pre-market up to authorization decision.
SPEAKER QUESTION: Lubna
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA authorization, multiplex tests, non-SARS-CoV-2 analytes
REVIEW FLAG: False

QA Block 8-5
CLARIFIED QUESTION: For non-SARS-CoV-2 analytes in a test seeking EUA, would validation need to include clinical sample sizes equivalent to what would be included in a cleared 510k level product?
CLARIFIED ANSWER: The FDA welcomes new multi-analyte panels with SARS-CoV-2 and requests additional data for non-SARS-CoV-2 targets if the panel is entirely new. Post-market commitments may include additional validation to align with full authorization standards while minimizing pre-market burdens.
VERBATIM QUESTION: For non-SARS-CoV-2 analytes in a test seeking EUA, would validation need to include clinical sample sizes equivalent to what would be included in a cleared 510k level product?
VERBATIM ANSWER: You're about 50% right. First of all absolutely we are welcoming any new panels that haven't been seen by us before as long as they have SARS-CoV-2 on it. We - because they're say for flu or RSV, there are current full authorized tests for those targets. We are asking for somebody who has not already gotten a panel authorized by the FDA, full authorization by the FDA and then they're adding SARS-CoV-2 to it, if someone's coming with an entirely new panel, maybe they're adding a panel to their previous SARS-CoV-2 test EUA, we want to see a little bit more data about those non-SARS-CoV-2 targets. And typically it has been the case where we have post-market commitments after EUA authorization to do additional studies on those target - on those non-SARS-CoV-2 targets in order to bring it up more in line with full authorization and enable an easier full authorization of those panels. So we want to provide assurances to everyone that the targets are working for those that have other full authorization. At the same time we want to make - be as least burdensome as possible and at least in the pre-market up to authorization decision.
SPEAKER QUESTION: Lubna
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation of non-SARS-CoV-2 analytes, EUA requirements for multiplex tests, Post-market validation commitments
REVIEW FLAG: False

QA Block 8-6
CLARIFIED QUESTION: What specific mitigations, such as labeling or training, would the FDA consider acceptable to allow for lower specificity in home tests?
CLARIFIED ANSWER: The FDA may consider lowering specificity requirements for home tests if mitigations like labeling or training are implemented.
VERBATIM QUESTION: What specific mitigations, such as labeling or training, would the FDA consider acceptable to allow for lower specificity in home tests?
VERBATIM ANSWER: On specificity of the home test we would entertain a lower specificity depending on other mitigations which maybe labeling and training -- things like that.
SPEAKER QUESTION: Lubna
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home test specificity, mitigation measures, FDA considerations
REVIEW FLAG: False

QA Block 8-7
CLARIFIED QUESTION: Does the FDA prioritize post-market commitments for non-SARS-CoV-2 analytes to ensure full authorization after an EUA is granted?
CLARIFIED ANSWER: The FDA commonly requires post-market commitments after EUA authorization to conduct additional studies on non-SARS-CoV-2 targets. This ensures these targets align with full authorization standards while minimizing pre-market burdens.
VERBATIM QUESTION: Does the FDA prioritize post-market commitments for non-SARS-CoV-2 analytes to ensure full authorization after an EUA is granted?
VERBATIM ANSWER: And typically it has been the case where we have post-market commitments after EUA authorization to do additional studies on those target - on those non-SARS-CoV-2 targets in order to bring it up more in line with full authorization and enable an easier full authorization of those panels. So we want to provide assurances to everyone that the targets are working for those that have other full authorization. At the same time we want to make - be as least burdensome as possible and at least in the pre-market up to authorization decision.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Post-market commitments, Non-SARS-CoV-2 analytes, EUA process
REVIEW FLAG: False

QA Block 8-8
CLARIFIED QUESTION: What level of additional data is required pre-market for new multi-analyte panels to meet EUA standards if they include non-SARS-CoV-2 targets?
CLARIFIED ANSWER: FDA requires additional pre-market data on non-SARS-CoV-2 targets for new multi-analyte panels, especially for those not previously authorized, and may allow some requirements to be addressed post-market.
VERBATIM QUESTION: What level of additional data is required pre-market for new multi-analyte panels to meet EUA standards if they include non-SARS-CoV-2 targets?
VERBATIM ANSWER: You're about 50% right. First of all absolutely we are welcoming any new panels that haven't been seen by us before as long as they have SARS-CoV-2 on it. We - because they're say for flu or RSV, there are current full authorized tests for those targets. We are asking for somebody who has not already gotten a panel authorized by the FDA, full authorization by the FDA and then they're adding SARS-CoV-2 to it, if someone's coming with an entirely new panel, maybe they're adding a panel to their previous SARS-CoV-2 test EUA, we want to see a little bit more data about those non-SARS-CoV-2 targets. And typically it has been the case where we have post-market commitments after EUA authorization to do additional studies on those target - on those non-SARS-CoV-2 targets in order to bring it up more in line with full authorization and enable an easier full authorization of those panels. So we want to provide assurances to everyone that the targets are working for those that have other full authorization. At the same time we want to make - be as least burdensome as possible and at least in the pre-market up to authorization decision.
SPEAKER QUESTION: Lubna
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA requirements, Multi-analyte panels, Non-SARS-CoV-2 validation
REVIEW FLAG: False

QA Block 8-9
CLARIFIED QUESTION: How does the FDA differentiate between EUA authorization requirements for respiratory panels that are adding SARS-CoV-2 versus entirely new panels?
CLARIFIED ANSWER: The FDA differentiates requirements by asking for more data on non-SARS-CoV-2 targets for entirely new panels, compared to panels adding SARS-CoV-2 to an already authorized test. Post-market commitments may also be required for further validation of non-SARS-CoV-2 targets.
VERBATIM QUESTION: How does the FDA differentiate between EUA authorization requirements for respiratory panels that are adding SARS-CoV-2 versus entirely new panels?
VERBATIM ANSWER: You're about 50% right. First of all absolutely we are welcoming any new panels that haven't been seen by us before as long as they have SARS-CoV-2 on it. We - because they're say for flu or RSV, there are current full authorized tests for those targets. We are asking for somebody who has not already gotten a panel authorized by the FDA, full authorization by the FDA and then they're adding SARS-CoV-2 to it, if someone's coming with an entirely new panel, maybe they're adding a panel to their previous SARS-CoV-2 test EUA, we want to see a little bit more data about those non-SARS-CoV-2 targets. And typically it has been the case where we have post-market commitments after EUA authorization to do additional studies on those target - on those non-SARS-CoV-2 targets in order to bring it up more in line with full authorization and enable an easier full authorization of those panels. So we want to provide assurances to everyone that the targets are working for those that have other full authorization. At the same time we want to make - be as least burdensome as possible and at least in the pre-market up to authorization decision.
SPEAKER QUESTION: Lubna
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA authorization, respiratory panels, validation requirements
REVIEW FLAG: False

QA Block 8-10
CLARIFIED QUESTION: What documentation or studies must developers submit to align non-SARS-CoV-2 targets with the goal of easier full authorization?
CLARIFIED ANSWER: FDA requires additional data on non-SARS-CoV-2 targets for entirely new panels, with post-market commitments for further studies to facilitate full authorization.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We are asking for somebody who has not already gotten a panel authorized by the FDA, full authorization by the FDA and then they're adding SARS-CoV-2 to it, if someone's coming with an entirely new panel, maybe they're adding a panel to their previous SARS-CoV-2 test EUA, we want to see a little bit more data about those non-SARS-CoV-2 targets. And typically it has been the case where we have post-market commitments after EUA authorization to do additional studies on those target - on those non-SARS-CoV-2 targets in order to bring it up more in line with full authorization and enable an easier full authorization of those panels. So we want to provide assurances to everyone that the targets are working for those that have other full authorization. At the same time we want to make - be as least burdensome as possible and at least in the pre-market up to authorization decision.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Non-SARS-CoV-2 validation, EUA authorization, FDA full authorization requirements
REVIEW FLAG: False


#### 9. Clarifying Distribution Channels for EUA Testing Kits

QA Block 9-1
CLARIFIED QUESTION: What is the most efficient way to obtain clarifications or modifications to an EUA for at-home testing?
CLARIFIED ANSWER: To obtain clarifications or modify an EUA for at-home testing, you need to add additional distributors through your lead reviewer or contact the FDA's mailbox for assistance.
VERBATIM QUESTION: What is the most efficient way to obtain clarifications or modifications to an EUA for at-home testing?
VERBATIM ANSWER: Yes that's something that you would just need to add additional distributors to your EUA. You could do that through your lead reviewer or reach out to the mailbox and we can help facilitate that.
SPEAKER QUESTION: Steven Kleiboeker (Eurofins)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA clarifications, at-home testing, additional distributors
REVIEW FLAG: False

QA Block 9-2
CLARIFIED QUESTION: What is meant by channels as opposed to distributors in the context of EUA distribution?
CLARIFIED ANSWER: Channels refer to brick-and-mortar pharmacies, as opposed to traditional distributors.
VERBATIM QUESTION: What is meant by channels as opposed to distributors in the context of EUA distribution?
VERBATIM ANSWER: So pharmacies. For example brick-and-mortar pharmacies.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Steven Kleiboeker (Eurofins)
TOPICS: EUA distribution, Channels vs distributors
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: Are pharmacies included as eligible distribution points under a CLIA-waived point-of-care device authorization?
CLARIFIED ANSWER: Pharmacies can serve as distribution points for CLIA-waived point-of-care devices, depending on the authorization of the device.
VERBATIM QUESTION: Are pharmacies included as eligible distribution points under a CLIA-waived point-of-care device authorization?
VERBATIM ANSWER: Oh. That would of course depend on your authorization. If you're a point of care device that can be - that's been deemed CLIA waived there's going to be no issue with distributing to pharmacies.
SPEAKER QUESTION: Steven Kleiboeker (Eurofins)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pharmacy distribution, CLIA-waived devices, authorization requirements
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: What are the requirements for allowing testing kits to be distributed through pharmacies instead of the manufacturer?
CLARIFIED ANSWER: To distribute testing kits through pharmacies, you need to add additional distributors to your EUA by working with your lead reviewer or contacting the FDA via the provided mailbox for facilitation.
VERBATIM QUESTION: What are the requirements for allowing testing kits to be distributed through pharmacies instead of the manufacturer?
VERBATIM ANSWER: Yes that's something that you would just need to add additional distributors to your EUA. You could do that through your lead reviewer or reach out to the mailbox and we can help facilitate that.
SPEAKER QUESTION: Steven Kleiboeker (Eurofins)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA modifications, Testing kit distribution, Pharmacy distribution channels
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: How can additional distributors be added to an existing EUA?
CLARIFIED ANSWER: To add additional distributors to an EUA, you need to contact your lead reviewer or reach out to the FDA's email mailbox for assistance.
VERBATIM QUESTION: How can additional distributors be added to an existing EUA?
VERBATIM ANSWER: Yes that's something that you would just need to add additional distributors to your EUA. You could do that through your lead reviewer or reach out to the mailbox and we can help facilitate that.
SPEAKER QUESTION: Steven Kleiboeker (Eurofins)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Adding distributors to EUA, EUA modification process
REVIEW FLAG: False

QA Block 9-6
CLARIFIED QUESTION: What are the specific limitations on distribution channels for an EUA-authorized high-complexity test?
CLARIFIED ANSWER: High-complexity tests cannot be distributed through pharmacies; they are not considered suitable distribution channels.
VERBATIM QUESTION: What are the specific limitations on distribution channels for an EUA-authorized high-complexity test?
VERBATIM ANSWER: Oh well yes if it's a high complexity test, pharmacies would not be an appropriate place to
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA limitations, distribution channels, high-complexity tests
REVIEW FLAG: False

QA Block 9-7
CLARIFIED QUESTION: Can self-collection kits for high-complexity tests be distributed through pharmacies when the testing is performed in a high-complexity laboratory?
CLARIFIED ANSWER: Self-collection kits for high-complexity tests cannot be distributed through pharmacies if the testing is performed in a high-complexity laboratory.
VERBATIM QUESTION: Can self-collection kits for high-complexity tests be distributed through pharmacies when the testing is performed in a high-complexity laboratory?
VERBATIM ANSWER: Oh well yes if it's a high complexity test, pharmacies would not be an appropriate place to
SPEAKER QUESTION: Steven Kleiboeker (Eurofins)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: self-collection kits, pharmacy distribution, high-complexity tests
REVIEW FLAG: False

QA Block 9-8
CLARIFIED QUESTION: How should test developers verify whether their distribution channels align with CLIA waiver requirements?
CLARIFIED ANSWER: Test developers should verify alignment by checking if their device authorization includes a CLIA waiver. If there are limitations or questions, the FDA recommends contacting their email address for clarification.
VERBATIM QUESTION: How should test developers verify whether their distribution channels align with CLIA waiver requirements?
VERBATIM ANSWER: Oh. That would of course depend on your authorization. If you're a point of care device that can be - that's been deemed CLIA waived there's going to be no issue with distributing to pharmacies. I - Toby do you know if we ask specifically about that or require that? So if you're being asked or being limited in some way by a member of our office or if you want further clarification, this is a specific enough question that I suggest you send it to our email address and ask for Toby and me and one of us will...
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA waiver requirements, distribution channels, test authorization
REVIEW FLAG: False

QA Block 9-9
CLARIFIED QUESTION: Is there a specific process to address scenarios where different distribution methods (e.g., pharmacies) are proposed for kit distribution?
CLARIFIED ANSWER: The FDA advises adding additional distributors to the EUA and suggests contacting the lead reviewer or the designated mailbox for assistance.
VERBATIM QUESTION: Is there a specific process to address scenarios where different distribution methods (e.g., pharmacies) are proposed for kit distribution?
VERBATIM ANSWER: Yes that's something that you would just need to add additional distributors to your EUA. You could do that through your lead reviewer or reach out to the mailbox and we can help facilitate that.
SPEAKER QUESTION: Steven Kleiboeker (Eurofins)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA modifications, distribution through pharmacies, adding distributors
REVIEW FLAG: False


#### 10. Authorization Requirements for Home Specimen Collection Devices

QA Block 10-1
CLARIFIED QUESTION: Does a specimen collection device used with an LDT need to be a legally marketed collection device?
CLARIFIED ANSWER: A specimen collection device used with an LDT must be a legally marketed device and must be legally marketed for its intended use. Labs using a device for SARS-CoV-2 testing should ensure it is either part of a test system or authorized as a standalone collection device, with regulatory responsibility assumed for the device.
VERBATIM QUESTION: Does a specimen collection device used with an LDT need to be a legally marketed collection device?
VERBATIM ANSWER: Regarding the specimen collection device correct, it does need to be a legally marketed collection device. And it needs to be legally marketed for the use it is being used for. So in that case you would need to - if a lab wants to use a collection device for SARS-CoV-2 testing there are not currently any drive-up spot collection devices that are authorized for that use. So they would need to come in either as a test system or the collection device as a standalone collection device. And they would need to take responsibility, regulatory responsibility for that collection device.
SPEAKER QUESTION: Sammy
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: specimen collection devices, LDT requirements, regulatory authorization
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: Would the collection device need its own EUA, or could it be part of an EUA assay?
CLARIFIED ANSWER: The collection device must be legally marketed for the intended use. If used for SARS-CoV-2 testing, it would either need to be part of a test system or authorized as a standalone collection device, with the entity taking regulatory responsibility.
VERBATIM QUESTION: Would the collection device need its own EUA, or could it be part of an EUA assay?
VERBATIM ANSWER: Regarding the specimen collection device correct, it does need to be a legally marketed collection device. And it needs to be legally marketed for the use it is being used for. So in that case you would need to - if a lab wants to use a collection device for SARS-CoV-2 testing there are not currently any drive-up spot collection devices that are authorized for that use. So they would need to come in either as a test system or the collection device as a standalone collection device. And they would need to take responsibility, regulatory responsibility for that collection device.
SPEAKER QUESTION: Sammy
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: collection device EUA, legally marketed devices, SARS-CoV-2 testing
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: What does it mean for a collection device to be legally marketed for the use it is being used for?
CLARIFIED ANSWER: A collection device must be legally marketed for its intended use. For SARS-CoV-2 testing, the device needs to be authorized, either as part of a test system or as a standalone device, and regulatory responsibility must be taken for it.
VERBATIM QUESTION: What does it mean for a collection device to be legally marketed for the use it is being used for?
VERBATIM ANSWER: It does need to be a legally marketed collection device. And it needs to be legally marketed for the use it is being used for. So in that case you would need to - if a lab wants to use a collection device for SARS-CoV-2 testing there are not currently any drive-up spot collection devices that are authorized for that use. So they would need to come in either as a test system or the collection device as a standalone collection device. And they would need to take responsibility, regulatory responsibility for that collection device.
SPEAKER QUESTION: Sammy
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: collection device authorization, SARS-CoV-2 testing, regulatory responsibilities
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: Are drive-up spot collection devices currently authorized for SARS-CoV-2 testing?
CLARIFIED ANSWER: Drive-up spot collection devices are not currently authorized for SARS-CoV-2 testing. To be authorized, they would need to come in as part of a test system or as a standalone collection device, with regulatory responsibility taken.
VERBATIM QUESTION: Are drive-up spot collection devices currently authorized for SARS-CoV-2 testing?
VERBATIM ANSWER: There are not currently any drive-up spot collection devices that are authorized for that use. So they would need to come in either as a test system or the collection device as a standalone collection device. And they would need to take responsibility, regulatory responsibility for that collection device.
SPEAKER QUESTION: Sammy
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Drive-up spot collection devices, Authorization requirements, SARS-CoV-2 testing
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: Can a laboratory take regulatory responsibility for a collection device as part of a test system?
CLARIFIED ANSWER: Yes, a laboratory can take regulatory responsibility for a collection device either as part of a test system or as a standalone device. The collection device must be legally marketed for the intended use.
VERBATIM QUESTION: Can a laboratory take regulatory responsibility for a collection device as part of a test system?
VERBATIM ANSWER: So for home collection, tests for home collection need to be authorized. They are not considered to be LDTs if they're for home collection. Regarding the specimen collection device correct, it does need to be a legally marketed collection device. And it needs to be legally marketed for the use it is being used for. So in that case you would need to - if a lab wants to use a collection device for SARS-CoV-2 testing there are not currently any drive-up spot collection devices that are authorized for that use. So they would need to come in either as a test system or the collection device as a standalone collection device. And they would need to take responsibility, regulatory responsibility for that collection device.
SPEAKER QUESTION: Sammy
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: collection devices for tests, regulatory responsibility, SARS-CoV-2 testing
REVIEW FLAG: False

QA Block 10-6
CLARIFIED QUESTION: What regulatory requirements must a collection device meet if it is submitted as a standalone collection device?
CLARIFIED ANSWER: A standalone collection device must be legally marketed for its intended use and the entity submitting it must take regulatory responsibility for the device.
VERBATIM QUESTION: What regulatory requirements must a collection device meet if it is submitted as a standalone collection device?
VERBATIM ANSWER: Regarding the specimen collection device correct, it does need to be a legally marketed collection device. And it needs to be legally marketed for the use it is being used for. So in that case you would need to - if a lab wants to use a collection device for SARS-CoV-2 testing there are not currently any drive-up spot collection devices that are authorized for that use. So they would need to come in either as a test system or the collection device as a standalone collection device. And they would need to take responsibility, regulatory responsibility for that collection device.
SPEAKER QUESTION: Sammy
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: collection device requirements, regulatory responsibility
REVIEW FLAG: False


#### 11. Authorization Requirements for Home Collection Kits

QA Block 11-1
CLARIFIED QUESTION: If we want to use the spectrum tube for home collection with an LDT, do we still need an EUA for the LDT with the spectrum tube for home collection?
CLARIFIED ANSWER: The spectrum tube is authorized as a standalone collection device but not as a home collection kit. For home collection, you would need to ensure the entire kit meets FDA requirements and obtain EUA authorization for all necessary aspects.
VERBATIM QUESTION: If we want to use the spectrum tube for home collection with an LDT, do we still need an EUA for the LDT with the spectrum tube for home collection?
VERBATIM ANSWER: So the spectrum tube by itself is not authorized as a home collection kit. So it is authorized as a standalone collection device but it does not include everything that we would expect to see in a home collection kit which would include, you know, how the kit is distributed, how it's received by the individual -- all of the steps that an individual needs to go through to make sure that they register the kit with the appropriate lab and collect the sample appropriately, package it up for shipping appropriately, get it back to the lab within the right timeframe -- all of those steps. And there's more information on what we look for in the home collection template. So the spectrum device, the way that it's authorized, it can be used, it can legally be used in a home collection kit. But the home collection kit as a whole does need to be authorized to capture all of those other aspects.
SPEAKER QUESTION: Kimberly Zunker
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: spectrum tube home collection, EUA requirements, LDT authorization
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: What are the specific requirements for a home collection kit to be authorized?
CLARIFIED ANSWER: The spectrum tube is not fully authorized as a home collection kit; it must meet additional requirements like proper distribution, user instructions, sample registration, appropriate packaging for shipping, and timely delivery to labs. Detailed criteria are in the FDA's home collection template.
VERBATIM QUESTION: What are the specific requirements for a home collection kit to be authorized?
VERBATIM ANSWER: So the spectrum tube by itself is not authorized as a home collection kit. So it is authorized as a standalone collection device but it does not include everything that we would expect to see in a home collection kit which would include, you know, how the kit is distributed, how it's received by the individual -- all of the steps that an individual needs to go through to make sure that they register the kit with the appropriate lab and collect the sample appropriately, package it up for shipping appropriately, get it back to the lab within the right timeframe -- all of those steps. And there's more information on what we look for in the home collection template. So the spectrum device, the way that it's authorized, it can be used, it can legally be used in a home collection kit. But the home collection kit as a whole does need to be authorized to capture all of those other aspects.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Home collection kits, Authorization requirements, Sample handling
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: What is included in the home collection template mentioned by the FDA?
CLARIFIED ANSWER: The FDA expects a home collection kit to include distribution methods, user instructions for registration with the lab, sample collection, packaging for shipment, and timely return to the lab. Additional details are in the home collection template.
VERBATIM QUESTION: What is included in the home collection template mentioned by the FDA?
VERBATIM ANSWER: So the spectrum tube by itself is not authorized as a home collection kit. So it is authorized as a standalone collection device but it does not include everything that we would expect to see in a home collection kit which would include, you know, how the kit is distributed, how it's received by the individual -- all of the steps that an individual needs to go through to make sure that they register the kit with the appropriate lab and collect the sample appropriately, package it up for shipping appropriately, get it back to the lab within the right timeframe -- all of those steps. And there's more information on what we look for in the home collection template.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Home collection template, EUA for LDTs, Diagnostic kit requirements
REVIEW FLAG: False

QA Block 11-4
CLARIFIED QUESTION: What steps does the FDA expect individuals to follow when using a home collection kit to ensure compliance?
CLARIFIED ANSWER: The FDA expects home collection kits to include proper distribution processes, instructions for registration with a lab, appropriate sample collection and packaging, and timely return to the lab. Authorization for the entire kit is required.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: So the spectrum tube by itself is not authorized as a home collection kit. So it is authorized as a standalone collection device but it does not include everything that we would expect to see in a home collection kit which would include, you know, how the kit is distributed, how it's received by the individual -- all of the steps that an individual needs to go through to make sure that they register the kit with the appropriate lab and collect the sample appropriately, package it up for shipping appropriately, get it back to the lab within the right timeframe -- all of those steps. And there's more information on what we look for in the home collection template. So the spectrum device, the way that it's authorized, it can be used, it can legally be used in a home collection kit. But the home collection kit as a whole does need to be authorized to capture all of those other aspects.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: home collection kits, FDA authorization, compliance steps
REVIEW FLAG: False

QA Block 11-5
CLARIFIED QUESTION: Can the spectrum tube be used as part of an authorized home collection kit, and if so, what additional steps are required for its use?
CLARIFIED ANSWER: The spectrum tube is not authorized as a standalone home collection kit but can legally be part of one. However, the home collection kit as a whole must be authorized, addressing aspects such as distribution, sample registration, proper packaging, and timely return to the lab. Details are available in the FDA's home collection template.
VERBATIM QUESTION: Can the spectrum tube be used as part of an authorized home collection kit, and if so, what additional steps are required for its use?
VERBATIM ANSWER: So the spectrum tube by itself is not authorized as a home collection kit. So it is authorized as a standalone collection device but it does not include everything that we would expect to see in a home collection kit which would include, you know, how the kit is distributed, how it's received by the individual -- all of the steps that an individual needs to go through to make sure that they register the kit with the appropriate lab and collect the sample appropriately, package it up for shipping appropriately, get it back to the lab within the right timeframe -- all of those steps. And there's more information on what we look for in the home collection template. So the spectrum device, the way that it's authorized, it can be used, it can legally be used in a home collection kit. But the home collection kit as a whole does need to be authorized to capture all of those other aspects.
SPEAKER QUESTION: Kimberly Zunker
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: spectrum tube authorization, home collection kits, authorization process
REVIEW FLAG: False


#### 12. Assessing Immune Response Post COVID-19 Vaccination

QA Block 12-1
CLARIFIED QUESTION: Could we anticipate any guidance from the FDA on how laboratorians are expected to assess immune status in those receiving COVID-19 vaccination regimens?
CLARIFIED ANSWER: The FDA's Center for Biologics (CBER) does not currently include diagnostics in vaccine approvals. No authorized diagnostic directly links to assessing immune status after COVID-19 vaccination, although neutralizing and semi-quantitative antibody tests may aid such research. Clinical studies are needed to support this indication, and FDA supports efforts to accumulate knowledge on serology tests for this purpose.
VERBATIM QUESTION: Could we anticipate any guidance from the FDA on how laboratorians are expected to assess immune status in those receiving COVID-19 vaccination regimens?
VERBATIM ANSWER: Yes so of course the Center for Biologics here at the FDA CBER is responsible for a vaccine reviews. They have typically signaled that they are not looking at any sort of diagnostic as part of vaccine approvals here. And but I'd also refer you to them but I believe that it's the thoughts. Now obviously that's an important research question. We have not authorized anything to date that would directly link to that. We've authorized some neutralizing antibody tests. We've authorized some semi quant test that may aid in the exploration and aid in the research of this question. You know, we are - the - in the manner in which you can directly support such an indication would be some sort of clinical study that might be fairly involved. And our focus on at least up to date for serology tests is to make available tests that we think are accurate that can be used for the - both the prescribed indications in the IFUs and make that resource available for additional research studies that may lead to additional uses for those tests. So I know that probably isn't too helpful to you. I, you know, I do know of efforts underway to try to address that question and the FDA would be supportive of at the very least accumulating knowledge around the usefulness of serology tests for this purpose. So again I doubt I really satisfied you in my response but I did want to be transparent to of where we are today.
SPEAKER QUESTION: Jack Maggiore
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: immune status assessment, COVID-19 vaccination, serology diagnostics
REVIEW FLAG: False

QA Block 12-2
CLARIFIED QUESTION: Could you clarify the expected period of time after the final dose to determine serologic response?
CLARIFIED ANSWER: The FDA has not yet authorized methods to determine the period after the final dose for serologic response. They support research in this area and have authorized some tests that may aid related investigations.
VERBATIM QUESTION: Could you clarify the expected period of time after the final dose to determine serologic response?
VERBATIM ANSWER: Yes so of course the Center for Biologics here at the FDA CBER is responsible for a vaccine reviews. They have typically signaled that they are not looking at any sort of diagnostic as part of vaccine approvals here. And but I'd also refer you to them but I believe that it's the thoughts. Now obviously that's an important research question. We have not authorized anything to date that would directly link to that. We've authorized some neutralizing antibody tests. We've authorized some semi quant test that may aid in the exploration and aid in the research of this question. You know, we are - the - in the manner in which you can directly support such an indication would be some sort of clinical study that might be fairly involved. And our focus on at least up to date for serology tests is to make available tests that we think are accurate that can be used for the - both the prescribed indications in the IFUs and make that resource available for additional research studies that may lead to additional uses for those tests. So I know that probably isn't too helpful to you. I, you know, I do know of efforts underway to try to address that question and the FDA would be supportive of at the very least accumulating knowledge around the usefulness of serology tests for this purpose. So again I doubt I really satisfied you in my response but I did want to be transparent to of where we are today.
SPEAKER QUESTION: Jack Maggiore
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serologic response timing, COVID-19 vaccine diagnostics, FDA authorization
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: Which antibodies specific for spike or nucleocapsid viral antigen should be identified to determine the effectiveness of the vaccine?
CLARIFIED ANSWER: The FDA has not authorized antibody diagnostics for directly determining vaccine effectiveness, though neutralizing antibody tests and semi-quantitative tests exist for research purposes. Determining effectiveness would require clinical studies, and the FDA supports research efforts in this area.
VERBATIM QUESTION: Which antibodies specific for spike or nucleocapsid viral antigen should be identified to determine the effectiveness of the vaccine?
VERBATIM ANSWER: Yes so of course the Center for Biologics here at the FDA CBER is responsible for a vaccine reviews. They have typically signaled that they are not looking at any sort of diagnostic as part of vaccine approvals here. And but I'd also refer you to them but I believe that it's the thoughts. Now obviously that's an important research question. We have not authorized anything to date that would directly link to that. We've authorized some neutralizing antibody tests. We've authorized some semi quant test that may aid in the exploration and aid in the research of this question. You know, we are - the - in the manner in which you can directly support such an indication would be some sort of clinical study that might be fairly involved. And our focus on at least up to date for serology tests is to make available tests that we think are accurate that can be used for the - both the prescribed indications in the IFUs and make that resource available for additional research studies that may lead to additional uses for those tests. So I know that probably isn't too helpful to you. I, you know, I do know of efforts underway to try to address that question and the FDA would be supportive of at the very least accumulating knowledge around the usefulness of serology tests for this purpose. So again I doubt I really satisfied you in my response but I did want to be transparent to of where we are today.
SPEAKER QUESTION: Jack Maggiore
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: vaccine effectiveness, antibodies for spike/nucleocapsid, serology tests
REVIEW FLAG: False

QA Block 12-4
CLARIFIED QUESTION: What is the expected signal or titer required to assess vaccine effectiveness?
CLARIFIED ANSWER: The FDA states that no specific diagnostic tests are authorized to determine vaccine effectiveness. Research and clinical studies are needed for this purpose, but some authorized antibody tests may aid in research.
VERBATIM QUESTION: What is the expected signal or titer required to assess vaccine effectiveness?
VERBATIM ANSWER: Yes so of course the Center for Biologics here at the FDA CBER is responsible for a vaccine reviews. They have typically signaled that they are not looking at any sort of diagnostic as part of vaccine approvals here. And but I'd also refer you to them but I believe that it's the thoughts. Now obviously that's an important research question. We have not authorized anything to date that would directly link to that. We've authorized some neutralizing antibody tests. We've authorized some semi quant test that may aid in the exploration and aid in the research of this question. You know, we are - the - in the manner in which you can directly support such an indication would be some sort of clinical study that might be fairly involved. And our focus on at least up to date for serology tests is to make available tests that we think are accurate that can be used for the - both the prescribed indications in the IFUs and make that resource available for additional research studies that may lead to additional uses for those tests. So I know that probably isn't too helpful to you.
SPEAKER QUESTION: Jack Maggiore
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: vaccine effectiveness, antibody diagnostics, research studies
REVIEW FLAG: False

QA Block 12-5
CLARIFIED QUESTION: Is there a possibility that FDA might approve or authorize diagnostics in the future that directly assess the effectiveness of COVID-19 vaccines?
CLARIFIED ANSWER: The FDA has not authorized diagnostics directly assessing vaccine effectiveness but has approved some tests aiding related research. Clinical studies would be needed for any such direct indications, and the FDA supports research into the utility of serology tests for this purpose.
VERBATIM QUESTION: Is there a possibility that FDA might approve or authorize diagnostics in the future that directly assess the effectiveness of COVID-19 vaccines?
VERBATIM ANSWER: Yes so of course the Center for Biologics here at the FDA CBER is responsible for a vaccine reviews. They have typically signaled that they are not looking at any sort of diagnostic as part of vaccine approvals here. And but I'd also refer you to them but I believe that it's the thoughts. Now obviously that's an important research question. We have not authorized anything to date that would directly link to that. We've authorized some neutralizing antibody tests. We've authorized some semi quant test that may aid in the exploration and aid in the research of this question. You know, we are - the - in the manner in which you can directly support such an indication would be some sort of clinical study that might be fairly involved. And our focus on at least up to date for serology tests is to make available tests that we think are accurate that can be used for the - both the prescribed indications in the IFUs and make that resource available for additional research studies that may lead to additional uses for those tests. So I know that probably isn't too helpful to you. I, you know, I do know of efforts underway to try to address that question and the FDA would be supportive of at the very least accumulating knowledge around the usefulness of serology tests for this purpose.
SPEAKER QUESTION: Jack Maggiore
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 vaccine diagnostics, serology tests, FDA approvals
REVIEW FLAG: False

QA Block 12-6
CLARIFIED QUESTION: What kind of clinical studies would be required to support diagnostics linked to vaccine effectiveness?
CLARIFIED ANSWER: Clinical studies to support diagnostics linked to vaccine effectiveness would be fairly involved. The FDA focuses on making accurate serology tests available for use under prescribed indications and for research that could expand their uses.
VERBATIM QUESTION: What kind of clinical studies would be required to support diagnostics linked to vaccine effectiveness?
VERBATIM ANSWER: You know, we are - the - in the manner in which you can directly support such an indication would be some sort of clinical study that might be fairly involved. And our focus on at least up to date for serology tests is to make available tests that we think are accurate that can be used for the - both the prescribed indications in the IFUs and make that resource available for additional research studies that may lead to additional uses for those tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: clinical studies, serology tests, vaccine effectiveness
REVIEW FLAG: False

QA Block 12-7
CLARIFIED QUESTION: Can serology tests currently authorized be used as part of research to determine their potential use in assessing vaccine responses?
CLARIFIED ANSWER: The FDA has not authorized serology tests specifically for assessing vaccine responses but has authorized neutralizing and semi-quantitative antibody tests, which may aid research. Any direct use for this purpose would require substantial clinical studies.
VERBATIM QUESTION: Can serology tests currently authorized be used as part of research to determine their potential use in assessing vaccine responses?
VERBATIM ANSWER: Now obviously that's an important research question. We have not authorized anything to date that would directly link to that. We've authorized some neutralizing antibody tests. We've authorized some semi quant test that may aid in the exploration and aid in the research of this question. You know, we are - the - in the manner in which you can directly support such an indication would be some sort of clinical study that might be fairly involved. And our focus on at least up to date for serology tests is to make available tests that we think are accurate that can be used for the - both the prescribed indications in the IFUs and make that resource available for additional research studies that may lead to additional uses for those tests. So I know that probably isn't too helpful to you. I, you know, I do know of efforts underway to try to address that question and the FDA would be supportive of at the very least accumulating knowledge around the usefulness of serology tests for this purpose.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology tests and research, Vaccine response assessment, FDA authorization
REVIEW FLAG: False

QA Block 12-8
CLARIFIED QUESTION: Does the FDA consider the development of semi-quantitative or neutralizing antibody tests as a priority for vaccine-related research?
CLARIFIED ANSWER: The FDA has authorized neutralizing and semi-quantitative antibody tests to aid in research but has not directly prioritized their use for assessing vaccine effectiveness. FDA supports research efforts to explore their utility.
VERBATIM QUESTION: Does the FDA consider the development of semi-quantitative or neutralizing antibody tests as a priority for vaccine-related research?
VERBATIM ANSWER: We've authorized some neutralizing antibody tests. We've authorized some semi quant test that may aid in the exploration and aid in the research of this question. You know, we are - the - in the manner in which you can directly support such an indication would be some sort of clinical study that might be fairly involved. And our focus on at least up to date for serology tests is to make available tests that we think are accurate that can be used for the - both the prescribed indications in the IFUs and make that resource available for additional research studies that may lead to additional uses for those tests. So I know that probably isn't too helpful to you. I, you know, I do know of efforts underway to try to address that question and the FDA would be supportive of at the very least accumulating knowledge around the usefulness of serology tests for this purpose.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: neutralizing antibody tests, semi-quantitative antibody tests, vaccine-related research
REVIEW FLAG: False


#### 13. Prescription vs. Over-the-Counter Antigen Test Requirements

QA Block 13-1
CLARIFIED QUESTION: What are the differences in performance required for a rapid antigen test to be designated as prescription versus nonprescription?
CLARIFIED ANSWER: For prescription tests, there may be age restrictions and validation for asymptomatic individuals is not generally required unless specifically claimed. Over-the-counter (OTC) tests must demonstrate accuracy for use by consumers, including use on asymptomatic and very young individuals, and safety for pediatric use. Minimal validation is needed, such as data from about 10 asymptomatic patients, and additional studies may be required post-market.
VERBATIM QUESTION: What are the differences in performance required for a rapid antigen test to be designated as prescription versus nonprescription?
VERBATIM ANSWER: So for rapid antigen tests in the home the prescription versus nonprescription, the prescription version can have some limitations. It may have an age limitation that for studies that validation perform say down to a certain age, you know, that the developer didn't at the time go any further down in age. And then of course we don't for any - for prescription based tests we do not have a recommendation to validate for asymptomatic patients other than if they want to make that specific claim. Then obviously if they want to make that specific claim that their test is authorized for asymptomatic screening then we would want to see asymptomatic data. But for every other prescription-based test we do not recommend validation in the asymptomatic population. However if you go to an entirely OTC over-the-counter direct to consumer where there is not a healthcare provider involved, the consumer decides that test is going to be performed on whether it's a symptomatic or an asymptomatic, the consumer gets to - is, you know, is going to be the one interpreting the test results for their situation. And so it - we look for evidence that that can all be done accurately. And of course in the home situation the consumer decides can do it on even very young individuals and on asymptomatic. So for OTC claims we are asking for and we're very - the burden is very low here. It's usually a minimum of about ten asymptomatic patients premarket authorization with sometimes additional post-market test, post-market studies. And then also if it's going to be used OTC in the home, we have to assume it's going to be used on kids. And so we want to see that it performs well in kids and that it's safe to perform in kids.
SPEAKER QUESTION: Daniel Roth (Actimed)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Rapid antigen test performance, Prescription vs nonprescription, OTC validation requirements
REVIEW FLAG: False

QA Block 13-2
CLARIFIED QUESTION: What are the validation requirements for a test to be authorized for asymptomatic screening use in the prescription category?
CLARIFIED ANSWER: The FDA does not require prescription-based tests to be validated for asymptomatic screening unless the developer specifically wants to make that claim, in which case asymptomatic data must be provided.
VERBATIM QUESTION: What are the validation requirements for a test to be authorized for asymptomatic screening use in the prescription category?
VERBATIM ANSWER: And then of course we don't for any - for prescription based tests we do not have a recommendation to validate for asymptomatic patients other than if they want to make that specific claim. Then obviously if they want to make that specific claim that their test is authorized for asymptomatic screening then we would want to see asymptomatic data.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation for asymptomatic use, Prescription vs nonprescription tests
REVIEW FLAG: False

QA Block 13-3
CLARIFIED QUESTION: What additional evidence is required to validate over-the-counter COVID-19 diagnostic tests for use in asymptomatic individuals?
CLARIFIED ANSWER: The FDA requires a minimum of evidence from about ten asymptomatic patients for premarket authorization, with possible additional post-market studies, to validate over-the-counter COVID-19 tests for asymptomatic use. Performance and safety in children are also evaluated since these tests can be used on all ages at home.
VERBATIM QUESTION: What additional evidence is required to validate over-the-counter COVID-19 diagnostic tests for use in asymptomatic individuals?
VERBATIM ANSWER: However if you go to an entirely OTC over-the-counter direct to consumer where there is not a healthcare provider involved, the consumer decides that test is going to be performed on whether it's a symptomatic or an asymptomatic, the consumer gets to - is, you know, is going to be the one interpreting the test results for their situation. And so it - we look for evidence that that can all be done accurately. And of course in the home situation the consumer decides can do it on even very young individuals and on asymptomatic. So for OTC claims we are asking for and we're very - the burden is very low here. It's usually a minimum of about ten asymptomatic patients premarket authorization with sometimes additional post-market test, post-market studies. And then also if it's going to be used OTC in the home, we have to assume it's going to be used on kids. And so we want to see that it performs well in kids and that it's safe to perform in kids.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC COVID-19 tests, Asymptomatic validation, Pediatric safety
REVIEW FLAG: False

QA Block 13-4
CLARIFIED QUESTION: What are the requirements to demonstrate that an over-the-counter test is safe and effective in children?
CLARIFIED ANSWER: FDA requires over-the-counter tests to demonstrate that they perform well and are safe for use in children.
VERBATIM QUESTION: What are the requirements to demonstrate that an over-the-counter test is safe and effective in children?
VERBATIM ANSWER: And then also if it's going to be used OTC in the home, we have to assume it's going to be used on kids. And so we want to see that it performs well in kids and that it's safe to perform in kids. So hopefully that addresses at a high level your questions and with some specificity.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC test safety for children, Performance validation in kids
REVIEW FLAG: False

QA Block 13-5
CLARIFIED QUESTION: What post-market study requirements exist for over-the-counter diagnostic tests for home use?
CLARIFIED ANSWER: FDA requires a minimum of about ten asymptomatic patients for premarket authorization for OTC diagnostic tests, with occasional additional post-market studies. For home use, tests must also demonstrate safety and effectiveness in children.
VERBATIM QUESTION: What post-market study requirements exist for over-the-counter diagnostic tests for home use?
VERBATIM ANSWER: So for OTC claims we are asking for and we're very - the burden is very low here. It's usually a minimum of about ten asymptomatic patients premarket authorization with sometimes additional post-market test, post-market studies. And then also if it's going to be used OTC in the home, we have to assume it's going to be used on kids. And so we want to see that it performs well in kids and that it's safe to perform in kids.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC diagnostic tests, post-market requirements, safety for children
REVIEW FLAG: False


#### 14. Progress and Challenges in Serology Test Authorization

QA Block 14-1
CLARIFIED QUESTION: Is there any hope that the serology test emergency use authorization application will be reviewed since we haven't even been assigned a primary reviewer yet?
CLARIFIED ANSWER: The FDA has received many serology applications and, due to resource limitations, is addressing them as rapidly as possible, aided by recent staff increases. Progress is evident, with about 65 decisions on serology tests made in the last two weeks.
VERBATIM QUESTION: Is there any hope that the serology test emergency use authorization application will be reviewed since we haven't even been assigned a primary reviewer yet?
VERBATIM ANSWER: Yes so of course we have received literally hundreds of serology, in particular serology lateral flow submissions. And it is a resource limitation situation. With the recent surge as I described at the beginning of the call, we are making significant progress across the office and including the serology decisions. So we have in the last two weeks made -- let's see if I can do the math 20, 40, it looks to me like about 65 serology decisions in the last two weeks. So that is evidence that we are - the surge is working and we're going to be able to as rapidly as possible with additional resources that we have, we have with the last surge we again doubled our number of people on COVID applications. And unfortunately for those developers who have non-COVID applications into the agency at least some of them and/or will be submitting non-COVID applications, those applications could be impacted. So it's this balance of how much resources do we put on COVID versus non-COVID when people continue to have other health care problems besides COVID.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA applications, Serology test reviews, FDA resource limitations
REVIEW FLAG: False

QA Block 14-2
CLARIFIED QUESTION: Why are there only 61 serology tests authorized so far if you mentioned 65 serology decisions were made in the last two weeks?
CLARIFIED ANSWER: FDA declined to clarify why there is a discrepancy between the number of serology tests authorized and the number of serology decisions mentioned.
VERBATIM QUESTION: Why are there only 61 serology tests authorized so far if you mentioned 65 serology decisions were made in the last two weeks?
VERBATIM ANSWER: I'll let you conclude for what that means. Next caller please.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test authorization, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 14-3
CLARIFIED QUESTION: What factors determine if a serology test EUA application is assigned a higher priority?
CLARIFIED ANSWER: FDA prioritizes serology EUA applications based on resource availability, progress from recent surges, and the overall balance between COVID and non-COVID healthcare needs.
VERBATIM QUESTION: What factors determine if a serology test EUA application is assigned a higher priority?
VERBATIM ANSWER: Yes so of course we have received literally hundreds of serology, in particular serology lateral flow submissions. And it is a resource limitation situation. With the recent surge as I described at the beginning of the call, we are making significant progress across the office and including the serology decisions. So we have in the last two weeks made -- let's see if I can do the math 20, 40, it looks to me like about 65 serology decisions in the last two weeks. So that is evidence that we are - the surge is working and we're going to be able to as rapidly as possible with additional resources that we have, we have with the last surge we again doubled our number of people on COVID applications. And unfortunately for those developers who have non-COVID applications into the agency at least some of them and/or will be submitting non-COVID applications, those applications could be impacted. So it's this balance of how much resources do we put on COVID versus non-COVID when people continue to have other health care problems besides COVID.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology EUA prioritization, resource limitations, COVID vs non-COVID priorities
REVIEW FLAG: False

QA Block 14-4
CLARIFIED QUESTION: How are resources being allocated between COVID and non-COVID applications?
CLARIFIED ANSWER: FDA has doubled COVID application staff but acknowledges that non-COVID applications might face delays due to resource allocation.
VERBATIM QUESTION: How are resources being allocated between COVID and non-COVID applications?
VERBATIM ANSWER: With the recent surge as I described at the beginning of the call, we are making significant progress across the office and including the serology decisions. So we have in the last two weeks made -- let's see if I can do the math 20, 40, it looks to me like about 65 serology decisions in the last two weeks. So that is evidence that we are - the surge is working and we're going to be able to as rapidly as possible with additional resources that we have, we have with the last surge we again doubled our number of people on COVID applications. And unfortunately for those developers who have non-COVID applications into the agency at least some of them and/or will be submitting non-COVID applications, those applications could be impacted. So it's this balance of how much resources do we put on COVID versus non-COVID when people continue to have other health care problems besides COVID.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Resource allocation, COVID vs non-COVID applications, Staffing impact
REVIEW FLAG: False

QA Block 14-6
CLARIFIED QUESTION: Does the FDA have plans to increase staffing further to manage the backlog of applications?
CLARIFIED ANSWER: The FDA has recently doubled the staffing for COVID applications, which has helped them significantly progress with serology test reviews.
VERBATIM QUESTION: Does the FDA have plans to increase staffing further to manage the backlog of applications?
VERBATIM ANSWER: With the recent surge as I described at the beginning of the call, we are making significant progress across the office and including the serology decisions. So we have in the last two weeks made -- let's see if I can do the math 20, 40, it looks to me like about 65 serology decisions in the last two weeks. So that is evidence that we are - the surge is working and we're going to be able to as rapidly as possible with additional resources that we have, we have with the last surge we again doubled our number of people on COVID applications.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: staffing, COVID-19 applications, resource allocation
REVIEW FLAG: False

QA Block 14-7
CLARIFIED QUESTION: How does the FDA define progress in making determinations for serology test applications?
CLARIFIED ANSWER: The FDA considers completing approximately 65 serology determinations in two weeks as evidence of progress, aided by increased resources and staff focused on COVID applications.
VERBATIM QUESTION: How does the FDA define progress in making determinations for serology test applications?
VERBATIM ANSWER: Yes so of course we have received literally hundreds of serology, in particular serology lateral flow submissions. And it is a resource limitation situation. With the recent surge as I described at the beginning of the call, we are making significant progress across the office and including the serology decisions. So we have in the last two weeks made -- let's see if I can do the math 20, 40, it looks to me like about 65 serology decisions in the last two weeks. So that is evidence that we are - the surge is working and we're going to be able to as rapidly as possible with additional resources that we have, we have with the last surge we again doubled our number of people on COVID applications.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test determinations, resource allocation
REVIEW FLAG: False


#### 15. Retrospective Sample Use and Low Positive Guidelines

QA Block 15-1
CLARIFIED QUESTION: What is the highest CT value recommended for low positive retrospective samples?
CLARIFIED ANSWER: The CT value for low positive samples typically exceeds 30, but specific recommendations depend on the comparator assay. The FDA suggests contacting a primary reviewer or using the templates email for guidance on specific molecular comparators.
VERBATIM QUESTION: What is the highest CT value recommended for low positive retrospective samples?
VERBATIM ANSWER: And then as far as low positive goes that is going to somewhat depend on your comparator. We do - we take a look at the LOG of that assay and the cut off of that assay to give you comparator specific ranges for low positives. So typically that has been over - CTs of over 30 but there could be specific situations where that advice may be a little bit different. And so I would engage with your primary reviewer or through the templates email box about a specific molecular comparator test and what low positive means for that okay?
SPEAKER QUESTION: Wendy Strongen
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CT value for low positive samples, Retrospective sample thresholds
REVIEW FLAG: False

QA Block 15-2
CLARIFIED QUESTION: For point-of-care rapid antigen tests, is a retrospective study sufficient if it includes five fresh positive samples?
CLARIFIED ANSWER: FDA allows retrospective studies for point-of-care rapid antigen tests as long as there are five fresh positive samples demonstrating adequate performance. The fresh samples must be properly distributed across test sites and user groups.
VERBATIM QUESTION: For point-of-care rapid antigen tests, is a retrospective study sufficient if it includes five fresh positive samples?
VERBATIM ANSWER: So the five fresh samples - and I apologize to you or whoever else called before about the low positive, the fresh sample doesn't - you may not get - the fresh positive may not be as well distributed as we wanted as far as the testing goes. So you can distribute the bands testing across the recommended number of sites and users. So yes, so and it's five positive fresh, not five overall fresh. We are looking for adequate performance in fresh samples.
SPEAKER QUESTION: Wendy Strongen
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Rapid Antigen Tests, Retrospective Studies, Fresh Positive Samples
REVIEW FLAG: False

QA Block 15-3
CLARIFIED QUESTION: Does the template recommend a five to six person study to show that the intended population can use the test?
CLARIFIED ANSWER: The template allows for distributing testing across the recommended sites and users to evaluate usability by the intended population.
VERBATIM QUESTION: Does the template recommend a five to six person study to show that the intended population can use the test?
VERBATIM ANSWER: So you can distribute the bands testing across the recommended number of sites and users.
SPEAKER QUESTION: Wendy Strongen
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: usability studies, intended population evaluation
REVIEW FLAG: False

QA Block 15-4
CLARIFIED QUESTION: What does the FDA mean by distributing bands across the recommended number of sites and users?
CLARIFIED ANSWER: The FDA means that testing should involve bands distributed across the recommended number of sites and users to ensure adequate performance.
VERBATIM QUESTION: What does the FDA mean by distributing bands across the recommended number of sites and users?
VERBATIM ANSWER: So you can distribute the bands testing across the recommended number of sites and users.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test distribution, testing sites, user involvement
REVIEW FLAG: False

QA Block 15-5
CLARIFIED QUESTION: How should test developers demonstrate adequate performance in fresh positive samples?
CLARIFIED ANSWER: Test developers should demonstrate adequate performance in fresh positive samples using five fresh positives distributed across the recommended sites and users.
VERBATIM QUESTION: How should test developers demonstrate adequate performance in fresh positive samples?
VERBATIM ANSWER: So the five fresh samples - and I apologize to you or whoever else called before about the low positive, the fresh sample doesn't - you may not get - the fresh positive may not be as well distributed as we wanted as far as the testing goes. So you can distribute the bands testing across the recommended number of sites and users. So yes, so and it's five positive fresh, not five overall fresh. We are looking for adequate performance in fresh samples.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Fresh positive sample performance, Test site distribution
REVIEW FLAG: False

QA Block 15-6
CLARIFIED QUESTION: What are comparator-specific ranges for low positive results, and how does the FDA define them?
CLARIFIED ANSWER: The FDA defines low positives based on the comparator, considering the LOG and cutoff of the assay to determine comparator-specific ranges. CT values over 30 are typical, but this can vary. FDA recommends consulting with the primary reviewer for specific cases.
VERBATIM QUESTION: What are comparator-specific ranges for low positive results, and how does the FDA define them?
VERBATIM ANSWER: So the five fresh samples - and I apologize to you or whoever else called before about the low positive, the fresh sample doesn't - you may not get - the fresh positive may not be as well distributed as we wanted as far as the testing goes. So you can distribute the bands testing across the recommended number of sites and users. So yes, so and it's five positive fresh, not five overall fresh. We are looking for adequate performance in fresh samples. And then as far as low positive goes that is going to somewhat depend on your comparator. We do - we take a look at the LOG of that assay and the cut off of that assay to give you comparator specific ranges for low positives. So typically that has been over - CTs of over 30 but there could be specific situations where that advice may be a little bit different. And so I would engage with your primary reviewer or through the templates email box about a specific molecular comparator test and what low positive means for that okay?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: low positive result ranges, FDA definitions, comparator assays
REVIEW FLAG: False

QA Block 15-7
CLARIFIED QUESTION: In what situations might the FDA's guidance on CT values for low positive samples differ from the typical threshold?
CLARIFIED ANSWER: FDA typically considers low positive CT values to be over 30 but this can vary depending on the assay's limit of detection and specific comparators. Consult your FDA reviewer for assay-specific guidance.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: So the five fresh samples - and I apologize to you or whoever else called before about the low positive, the fresh sample doesn't - you may not get - the fresh positive may not be as well distributed as we wanted as far as the testing goes. So you can distribute the bands testing across the recommended number of sites and users. So yes, so and it's five positive fresh, not five overall fresh. We are looking for adequate performance in fresh samples. And then as far as low positive goes that is going to somewhat depend on your comparator. We do - we take a look at the LOG of that assay and the cut off of that assay to give you comparator specific ranges for low positives. So typically that has been over - CTs of over 30 but there could be specific situations where that advice may be a little bit different. And so I would engage with your primary reviewer or through the templates email box about a specific molecular comparator test and what low positive means for that okay?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CT values, low positive thresholds, molecular comparator tests
REVIEW FLAG: False

QA Block 15-8
CLARIFIED QUESTION: How should developers engage with the FDA when clarification is needed on low positive definitions for a specific molecular comparator test?
CLARIFIED ANSWER: Developers should engage with their primary FDA reviewer or use the templates email box for clarification on low positive definitions for a specific molecular comparator test, as guidance could vary based on the assay's characteristics.
VERBATIM QUESTION: How should developers engage with the FDA when clarification is needed on low positive definitions for a specific molecular comparator test?
VERBATIM ANSWER: And then as far as low positive goes that is going to somewhat depend on your comparator. We do - we take a look at the LOG of that assay and the cut off of that assay to give you comparator specific ranges for low positives. So typically that has been over - CTs of over 30 but there could be specific situations where that advice may be a little bit different. And so I would engage with your primary reviewer or through the templates email box about a specific molecular comparator test and what low positive means for that okay?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: low positive definitions, FDA engagement, molecular comparator tests
REVIEW FLAG: False


#### 16. Requirements for Performance Testing of Point-of-Care Antigen Tests

QA Block 16-1
CLARIFIED QUESTION: Is it sufficient to conduct performance testing for direct antigen tests in Europe, or are US test sites required?
CLARIFIED ANSWER: Performance testing for direct antigen tests can be conducted outside the US, but the FDA encourages US-based testing where possible. Such studies should also consider testing materials in English and Spanish.
VERBATIM QUESTION: Is it sufficient to conduct performance testing for direct antigen tests in Europe, or are US test sites required?
VERBATIM ANSWER: A point of care study. So we want the instructions, the rapid instructions that are provided to the consumer or to the point of care to be tested in both English and Spanish. Typically we allow that sort of study to be entirely outside the US. Where possible we would love to see US-based testing. We also are encouraging where possible to include the pediatric population in good age range. However, you know, we don't think currently that there is a difference between kids and adults. It's just if it is possible, we encourage that it's not something that will result in a denial premarket. So in short yes, you can perform that testing outside the US.
SPEAKER QUESTION: Douglas Ross
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Performance testing, International testing, Regulatory requirements
REVIEW FLAG: False

QA Block 16-2
CLARIFIED QUESTION: Is it necessary for the demographics of the study population to mirror those of the US?
CLARIFIED ANSWER: FDA requires studies for point of care in the US to reflect the US setting. For home or non-lab use, studies outside the US are acceptable with justification to demonstrate they reflect US users.
VERBATIM QUESTION: Is it necessary for the demographics of the study population to mirror those of the US?
VERBATIM ANSWER: Yes I believe - so I know that there's information in the antigen template. And I believe that we do for - sorry I'm not sure if you are talking about a test for point of care or for home use or non-lab use but for point of care where you would be at a CLIA, a site with a CLIA waiver certificate we would expect to see the point of care study done in the US to reflect that setting. For home use or non-lab use we would expect it to be reflective of US users. And so if it is done - if it is performed outside the US like Tim said we would just - we would expect to see justification for why that is still reflective of US users.
SPEAKER QUESTION: Douglas Ross
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: demographics in study population, US-based testing justification, non-lab/point of care studies
REVIEW FLAG: False

QA Block 16-3
CLARIFIED QUESTION: Does the requirement for testing apply not only to human factors but also to clinical validation?
CLARIFIED ANSWER: Yes, testing applies to both human factors and clinical validation. Studies for point of care should reflect US settings or users, even if conducted outside the US, with proper justification.
VERBATIM QUESTION: Does the requirement for testing apply not only to human factors but also to clinical validation?
VERBATIM ANSWER: Yes. Toby - and Toby sometimes corrects me or adds color to what I say. Yes I believe - so I know that there's information in the antigen template. And I believe that we do for - sorry I'm not sure if you are talking about a test for point of care or for home use or non-lab use but for point of care where you would be at a CLIA, a site with a CLIA waiver certificate we would expect to see the point of care study done in the US to reflect that setting. For home use or non-lab use we would expect it to be reflective of US users. And so if it is done - if it is performed outside the US like Tim said we would just - we would expect to see justification for why that is still reflective of US users.
SPEAKER QUESTION: Douglas Ross
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: testing requirements, clinical validation, human factors
REVIEW FLAG: False

QA Block 16-6
CLARIFIED QUESTION: What are the FDA requirements for testing instructions for point-of-care tests to ensure they are accessible to US users?
CLARIFIED ANSWER: The FDA requires point-of-care test instructions to be tested in both English and Spanish. While such studies can be conducted outside the US, US-based testing is encouraged where possible. Including a representative pediatric population is also encouraged but not mandatory.
VERBATIM QUESTION: What are the FDA requirements for testing instructions for point-of-care tests to ensure they are accessible to US users?
VERBATIM ANSWER: A point of care study. So we want the instructions, the rapid instructions that are provided to the consumer or to the point of care to be tested in both English and Spanish. Typically we allow that sort of study to be entirely outside the US. Where possible we would love to see US-based testing. We also are encouraging where possible to include the pediatric population in good age range. However, you know, we don't think currently that there is a difference between kids and adults. It's just if it is possible, we encourage that it's not something that will result in a denial premarket.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: point-of-care test instructions, language requirements, testing demographics
REVIEW FLAG: False

QA Block 16-7
CLARIFIED QUESTION: Is it mandatory to conduct studies that include a pediatric population for rapid antigen tests?
CLARIFIED ANSWER: Including pediatric populations in studies for rapid antigen tests is encouraged but not mandatory, as there is no current evidence of a difference in performance between children and adults.
VERBATIM QUESTION: Is it mandatory to conduct studies that include a pediatric population for rapid antigen tests?
VERBATIM ANSWER: We also are encouraging where possible to include the pediatric population in good age range. However, you know, we don't think currently that there is a difference between kids and adults. It's just if it is possible, we encourage that it's not something that will result in a denial premarket.
SPEAKER QUESTION: Douglas Ross
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pediatric studies, rapid antigen test requirements
REVIEW FLAG: False

QA Block 16-8
CLARIFIED QUESTION: What are the FDA's expectations regarding justifications for studies performed outside of the US for home use or point-of-care tests?
CLARIFIED ANSWER: The FDA expects point-of-care studies in CLIA-waived settings to be done in the US to reflect local settings. For home use or non-lab use, studies performed outside the US must provide justification to show they reflect US users.
VERBATIM QUESTION: What are the FDA's expectations regarding justifications for studies performed outside of the US for home use or point-of-care tests?
VERBATIM ANSWER: Yes I believe - so I know that there's information in the antigen template. And I believe that we do for - sorry I'm not sure if you are talking about a test for point of care or for home use or non-lab use but for point of care where you would be at a CLIA, a site with a CLIA waiver certificate we would expect to see the point of care study done in the US to reflect that setting. For home use or non-lab use we would expect it to be reflective of US users. And so if it is done - if it is performed outside the US like Tim said we would just - we would expect to see justification for why that is still reflective of US users.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: justifications for non-US studies, point-of-care tests, home use diagnostics
REVIEW FLAG: False

QA Block 16-9
CLARIFIED QUESTION: What constitutes a valid 'point-of-care' setting for FDA validation purposes?
CLARIFIED ANSWER: A valid 'point-of-care' setting for FDA validation reflects environments typical in the US, such as non-laboratory settings, primary care office staff, and non-laboratory physicians. High-complexity lab settings do not qualify as point-of-care settings.
VERBATIM QUESTION: What constitutes a valid 'point-of-care' setting for FDA validation purposes?
VERBATIM ANSWER: That's a great point Toby and I'll just give additional color to that. You know, in Europe the point of care sites and other parts of the world may not be similar to our point of care sites. So we have seen unfortunately "point of care studies" done in high complexity type lab environments and that is not a point of care study. We're looking at the types of users that would be in the US for point of care type of users that would be home use in the US truly in the home for example and truly in a point of care type situation with, you know, with non-laboratory physicians and other health practitioners and other primary care office staff type people.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point-of-care validation, Definition of setting, Non-laboratory environments
REVIEW FLAG: False

### removed qa blocks
QA Block 4-1  _reran - there is answer to this same question later_
CLARIFIED QUESTION: How high should the CT values be for low positives in retrospective studies of a rapid antigen test?
CLARIFIED ANSWER: The transcript does not provide an answer to the question about CT values for low positives in retrospective studies.
VERBATIM QUESTION: How high should the CT values be for low positives in retrospective studies of a rapid antigen test?
VERBATIM ANSWER: NO RELEVANT ANSWER IN TRANSCRIPT
SPEAKER QUESTION: Wendy Strongen
SPEAKER ANSWER: NOT APPLICABLE
TOPICS: 
REVIEW FLAG: False

QA Block 14-5
CLARIFIED QUESTION: What criteria are used to classify serology tests as authorized versus decided within the FDA's records?
CLARIFIED ANSWER: The question regarding classification criteria was not explicitly addressed in this excerpt.
VERBATIM QUESTION: What criteria are used to classify serology tests as authorized versus decided within the FDA's records?
VERBATIM ANSWER: NO RELEVANT ANSWER IN TRANSCRIPT
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: NOT APPLICABLE
TOPICS: 
REVIEW FLAG: True

QA Block 16-4
CLARIFIED QUESTION: For point-of-care tests, does the FDA expect the study to be conducted in the US to reflect the US setting?
CLARIFIED ANSWER: The FDA expects point-of-care studies to be conducted in the US at sites with a CLIA waiver to reflect the US setting. If conducted outside the US, justification for how the study reflects US users is required.
VERBATIM QUESTION: For point-of-care tests, does the FDA expect the study to be conducted in the US to reflect the US setting?
VERBATIM ANSWER: Yes I believe - so I know that there's information in the antigen template. And I believe that we do for - sorry I'm not sure if you are talking about a test for point of care or for home use or non-lab use but for point of care where you would be at a CLIA, a site with a CLIA waiver certificate we would expect to see the point of care study done in the US to reflect that setting. For home use or non-lab use we would expect it to be reflective of US users. And so if it is done - if it is performed outside the US like Tim said we would just - we would expect to see justification for why that is still reflective of US users.
SPEAKER QUESTION: Douglas Ross
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Point-of-care studies, Location of testing, Reflecting US settings
REVIEW FLAG: False

QA Block 16-5
CLARIFIED QUESTION: For home use or non-laboratory use tests conducted outside the US, what justification is required to reflect US users?
CLARIFIED ANSWER: For home or non-laboratory use tests conducted outside the US, FDA requires justification explaining how the study reflects US users.
VERBATIM QUESTION: For home use or non-laboratory use tests conducted outside the US, what justification is required to reflect US users?
VERBATIM ANSWER: Yes I believe - so I know that there's information in the antigen template. And I believe that we do for - sorry I'm not sure if you are talking about a test for point of care or for home use or non-lab use but for point of care where you would be at a CLIA, a site with a CLIA waiver certificate we would expect to see the point of care study done in the US to reflect that setting. For home use or non-lab use we would expect it to be reflective of US users. And so if it is done - if it is performed outside the US like Tim said we would just - we would expect to see justification for why that is still reflective of US users.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Home use testing, Study justification, US user relevance
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2024-12-30 06:49:50 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 16
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 1-1: What are the specific caveats about the use of pooling that test developers should be aware of?
QI 1-2: Can tests be used off-label if they have no specific use limitations, and what constitutes a specific limitation on use?
QI 1-3: Are there any emerging data or guidelines supporting the use of panel tests for SARS-CoV-2 and flu detection?
QI 1-4: What types of testing methodologies or formats does the FDA prioritize for SARS-CoV-2 diagnostics?
QI 1-5: What does the FDA consider a high-throughput system for efficient testing of large sample volumes?

#### Section 2 of 16
##### Explicit Questions Extraction
QE 2-1: Can you provide guidance on the use of a consolidated primer set for a LAMP-based assay, specifically addressing inclusivity in silico analysis, in silico cross-reactivity, and wet cross-reactivity?
QE 2-2: If we get authorization for a test using one type of activation buffer and purification method, and another developer pursues authorization with a different purification method but the same primer set and LAMP master mix, would they need to repeat the interfering substances testing?
QE 2-3: If we provide another developer a general right of reference for our test, allowing them to get their own EUA and control their own designations, while we maintain our own separate EUA and designations, is that the correct process?

##### Implicit Questions Extraction
QI 2-1: What are the specific criteria the FDA uses to determine when additional validation is required for alterations to an EUA authorized test?
QI 2-2: Does the use of a shared primer set with identical suppliers and catalog numbers eliminate the need for independent validations for each developer?
QI 2-3: What commitments are required from developers in a model where they designate laboratories for use of their authorized test?
QI 2-4: Under what circumstances would a developer opting for the saliva direct open-source model still need to perform new validations?
QI 2-5: Can the FDA clarify the flexibility extended to developers adopting a model similar to the Yale saliva direct approach?
QI 2-6: What processes do developers need to follow to give specific or limited rights of reference to another developer?
QI 2-7: What elements of a test's core components are necessary to remain unchanged to reduce duplication of validation efforts?

#### Section 3 of 16
##### Explicit Questions Extraction
QE 3-1: Does the FDA agree that point-of-care facilities can use both fingerstick and venous draw whole blood but not plasma and serum for antibody test kits authorized for point-of-care use?

##### Implicit Questions Extraction
QI 3-1: Can devices designed to use plasma or serum be adapted for point-of-care use?
QI 3-2: What are the training requirements or limitations for point-of-care facilities when handling specific types of diagnostic specimens?
QI 3-3: Are there any restrictions on point-of-care facilities using certain types of blood specimens like venous draw whole blood?

#### Section 4 of 16
##### Explicit Questions Extraction
QE 4-1: How high should the CT values be for low positives in retrospective studies of a rapid antigen test?
QE 4-2: Do you still recommend five fresh samples for retrospective studies if dry fresh swabs, not in VTM but frozen, are used?

##### Implicit Questions Extraction
QI 4-1: Does the FDA allow flexibility for completing fresh sample studies for retrospective studies post-market?
QI 4-2: Does the freeze-thaw process of swabs affect assay performance or target availability in a way that impacts study design or results?
QI 4-3: Why is it considered impractical to require freezing swabs for point-of-care sites?

#### Section 5 of 16
##### Explicit Questions Extraction
QE 5-1: Do you have information about tests mentioned by President Trump that don't require doctors to administer the test?
QE 5-2: Are these tests that don't involve healthcare professionals similar to the ones we already have or are they true over-the-counter tests for COVID-19?

##### Implicit Questions Extraction
QI 5-1: What are the FDA's validation recommendations for over-the-counter or direct-to-consumer COVID-19 tests?
QI 5-2: Are there currently any FDA authorizations for COVID-19 diagnostic tests that do not require a prescription?
QI 5-3: Why does the FDA set higher performance requirements for tests not involving healthcare professionals?

#### Section 6 of 16
##### Explicit Questions Extraction
QE 6-1: What extent of software validation is required for a support vector machine used in COVID-19 assay classification?
QE 6-2: Does the FDA require typical co-documentation for software validation, such as testing analysis, requirement specifications, design specifications, and the full validation suite?
QE 6-3: If each end user calibrates the AI algorithm to their instrument, should the calibration set be included in a change plan like a software as a medical device pre-specification or algorithm change protocols?
QE 6-4: How in-depth is the software validation expected to be, given the molecular template states the software should be validated as free of defects but acknowledges no software can truly be free of defects?

##### Implicit Questions Extraction
QI 6-1: Does the FDA recommend differing levels of software documentation for EUA submissions compared to full authorizations?
QI 6-2: What constitutes the most critical software components that should be focused on prior to EUA authorization for COVID-19 assays?
QI 6-3: How does the intended use or point-of-care setting influence the FDA's software validation recommendations for diagnostic devices?
QI 6-4: Does engaging in early communication with the FDA reduce the chances of delays caused by over-preparing documentation?

#### Section 7 of 16
##### Explicit Questions Extraction
QE 7-1: Is registration of the saliva collection device with the FDA sufficient to use it with any EUA-approved saliva tests?
QE 7-2: __If a saliva collection device is an empty tube__ with no preservatives or coatings, does it require FDA authorization?

##### Implicit Questions Extraction
QI 7-1: What requirements apply if a test developer includes a commercially available sterile tube, with no RNA preservation claims, as part of their test?
QI 7-2: What are the performance demonstration requirements for an empty sterile tube a manufacturer markets for RNA preservation?
QI 7-3: Do devices marketed for RNA preservation, regardless of explicit SARS-CoV-2 claims, still require FDA authorization?
QI 7-4: Is FDA review required for any device that makes claims about saliva collection for SARS-CoV-2 testing?

#### Section 8 of 16
##### Explicit Questions Extraction
QE 8-1: What is the performance feature required to obtain an OTC non-prescribed indication versus an Rx non-lab use claimed indication?
QE 8-2: Is the asymptomatic subject NPA of 99% the reason that current non-lab use tests are prescription use only?
QE 8-3: Is the asymptomatic subject NPA of 99% the key performance discriminator holding up true OTC authorization?
QE 8-4: Are you open to receiving a test that is not an already cleared multiplex test that includes multiple analytes like SARS-CoV-2 and RSV for EUA authorization?
QE 8-5: For non-SARS-CoV-2 analytes in a test seeking EUA, would validation need to include clinical sample sizes equivalent to what would be included in a cleared 510k level product?

##### Implicit Questions Extraction
QI 8-1: What specific mitigations, such as labeling or training, would the FDA consider acceptable to allow for lower specificity in home tests?
QI 8-2: Does the FDA prioritize post-market commitments for non-SARS-CoV-2 analytes to ensure full authorization after an EUA is granted?
QI 8-3: What level of additional data is required pre-market for new multi-analyte panels to meet EUA standards if they include non-SARS-CoV-2 targets?
QI 8-4: How does the FDA differentiate between EUA authorization requirements for respiratory panels that are adding SARS-CoV-2 versus entirely new panels?
QI 8-5: What documentation or studies must developers submit to align non-SARS-CoV-2 targets with the goal of easier full authorization?

#### Section 9 of 16
##### Explicit Questions Extraction
QE 9-1: What is the most efficient way to obtain clarifications or modifications to an EUA for at-home testing?
QE 9-2: What is meant by channels as opposed to distributors in the context of EUA distribution?
QE 9-3: Are pharmacies included as eligible distribution points under a CLIA-waived point-of-care device authorization?
QE 9-4: What are the requirements for allowing testing kits to be distributed through pharmacies instead of the manufacturer?
QE 9-5: How can additional distributors be added to an existing EUA?

##### Implicit Questions Extraction
QI 9-1: What are the specific limitations on distribution channels for an EUA-authorized high-complexity test?
QI 9-2: Can self-collection kits for high-complexity tests be distributed through pharmacies when the testing is performed in a high-complexity laboratory?
QI 9-3: How should test developers verify whether their distribution channels align with CLIA waiver requirements?
QI 9-4: Is there a specific process to address scenarios where different distribution methods (e.g., pharmacies) are proposed for kit distribution?

#### Section 10 of 16
##### Explicit Questions Extraction
QE 10-1: Does a specimen collection device used with an LDT need to be a legally marketed collection device?
QE 10-2: Would the collection device need its own EUA, or could it be part of an EUA assay?

##### Implicit Questions Extraction
QI 10-1: What does it mean for a collection device to be legally marketed for the use it is being used for?
QI 10-2: Are drive-up spot collection devices currently authorized for SARS-CoV-2 testing?
QI 10-3: Can a laboratory take regulatory responsibility for a collection device as part of a test system?
QI 10-4: What regulatory requirements must a collection device meet if it is submitted as a standalone collection device?

#### Section 11 of 16
##### Explicit Questions Extraction
QE 11-1: If we want to use the spectrum tube for home collection with an LDT, do we still need an EUA for the LDT with the spectrum tube for home collection?

##### Implicit Questions Extraction
QI 11-1: What are the specific requirements for a home collection kit to be authorized?
QI 11-2: What is included in the home collection template mentioned by the FDA?
QI 11-3: What steps does the FDA expect individuals to follow when using a home collection kit to ensure compliance?
QI 11-4: Can the spectrum tube be used as part of an authorized home collection kit, and if so, what additional steps are required for its use?

#### Section 12 of 16  _Good that this is 4 now_
##### Explicit Questions Extraction
QE 12-1: Could we anticipate any guidance from the FDA on how laboratorians are expected to assess immune status in those receiving COVID-19 vaccination regimens?
QE 12-2: Could you clarify the expected period of time after the final dose to determine serologic response?
QE 12-3: Which antibodies specific for spike or nucleocapsid viral antigen should be identified to determine the effectiveness of the vaccine?
QE 12-4: What is the expected signal or titer required to assess vaccine effectiveness?

##### Implicit Questions Extraction
QI 12-1: Is there a possibility that FDA might approve or authorize diagnostics in the future that directly assess the effectiveness of COVID-19 vaccines?
QI 12-2: What kind of clinical studies would be required to support diagnostics linked to vaccine effectiveness?
QI 12-3: Can serology tests currently authorized be used as part of research to determine their potential use in assessing vaccine responses?
QI 12-4: Does the FDA consider the development of semi-quantitative or neutralizing antibody tests as a priority for vaccine-related research?

#### Section 13 of 16
##### Explicit Questions Extraction
QE 13-1: What are the differences in performance required for a rapid antigen test to be designated as prescription versus nonprescription?

##### Implicit Questions Extraction
QI 13-1: What are the validation requirements for a test to be authorized for asymptomatic screening use in the prescription category?
QI 13-2: What additional evidence is required to validate over-the-counter COVID-19 diagnostic tests for use in asymptomatic individuals?
QI 13-3: What are the requirements to demonstrate that an over-the-counter test is safe and effective in children?
QI 13-4: What post-market study requirements exist for over-the-counter diagnostic tests for home use?

#### Section 14 of 16
##### Explicit Questions Extraction
QE 14-1: Is there any hope that the serology test emergency use authorization application will be reviewed since we haven't even been assigned a primary reviewer yet?
QE 14-2: Why are there only 61 serology tests authorized so far if you mentioned 65 serology decisions were made in the last two weeks?

##### Implicit Questions Extraction
QI 14-1: What factors determine if a serology test EUA application is assigned a higher priority?
QI 14-2: How are resources being allocated between COVID and non-COVID applications?
QI 14-3: What criteria are used to classify serology tests as authorized versus decided within the FDA's records?
QI 14-4: Does the FDA have plans to increase staffing further to manage the backlog of applications?
QI 14-5: How does the FDA define progress in making determinations for serology test applications?

#### Section 15 of 16
##### Explicit Questions Extraction
QE 15-1: What is the highest CT value recommended for low positive retrospective samples?
QE 15-2: For point-of-care rapid antigen tests, is a retrospective study sufficient if it includes five fresh positive samples?
QE 15-3: Does the template recommend a five to six person study to show that the intended population can use the test?

##### Implicit Questions Extraction
QI 15-1: What does the FDA mean by distributing bands across the recommended number of sites and users?
QI 15-2: How should test developers demonstrate adequate performance in fresh positive samples?
QI 15-3: What are comparator-specific ranges for low positive results, and how does the FDA define them?
QI 15-4: In what situations might the FDA's guidance on CT values for low positive samples differ from the typical threshold?
QI 15-5: How should developers engage with the FDA when clarification is needed on low positive definitions for a specific molecular comparator test?

#### Section 16 of 16
##### Explicit Questions Extraction
QE 16-1: Is it sufficient to conduct performance testing for direct antigen tests in Europe, or are US test sites required?
QE 16-2: Is it necessary for the demographics of the study population to mirror those of the US?
QE 16-3: Does the requirement for testing apply not only to human factors but also to clinical validation?
QE 16-4: For point-of-care tests, does the FDA expect the study to be conducted in the US to reflect the US setting?
QE 16-5: For home use or non-laboratory use tests conducted outside the US, what justification is required to reflect US users?

##### Implicit Questions Extraction
QI 16-1: What are the FDA requirements for testing instructions for point-of-care tests to ensure they are accessible to US users?
QI 16-2: Is it mandatory to conduct studies that include a pediatric population for rapid antigen tests?
QI 16-3: What are the FDA's expectations regarding justifications for studies performed outside of the US for home use or point-of-care tests?
QI 16-4: What constitutes a valid 'point-of-care' setting for FDA validation purposes?

### deduplication
_consider setting at .77 or .78_

Showing question pairs above similarity threshold: .7

#### Section 7 similar questions (similarity > 0.7):
Q1 & Q6 (similarity: 0.737):
Q1: Is registration of the saliva collection device with the FDA sufficient to use it with any EUA-approved saliva tests?
Q6: Is FDA review required for any device that makes claims about saliva collection for SARS-CoV-2 testing?

Q3 & Q4 (similarity: 0.768):
Q3: What requirements apply if a test developer includes a commercially available sterile tube, with no RNA preservation claims, as part of their test?
Q4: What are the performance demonstration requirements for an empty sterile tube a manufacturer markets for RNA preservation?

#### Section 8 similar questions (similarity > 0.7):
Q2 & Q3 (similarity: 0.714):
Q2: Is the asymptomatic subject NPA of 99% the reason that current non-lab use tests are prescription use only?
Q3: Is the asymptomatic subject NPA of 99% the key performance discriminator holding up true OTC authorization?

#### Section 11 similar questions (similarity > 0.7):
Q1 & Q5 (similarity: 0.700):
Q1: If we want to use the spectrum tube for home collection with an LDT, do we still need an EUA for the LDT with the spectrum tube for home collection?
Q5: Can the spectrum tube be used as part of an authorized home collection kit, and if so, what additional steps are required for its use?

#### Section 16 similar questions (similarity > 0.7):
Q4 & Q6 (similarity: 0.718):
Q4: For point-of-care tests, does the FDA expect the study to be conducted in the US to reflect the US setting?
Q6: What are the FDA requirements for testing instructions for point-of-care tests to ensure they are accessible to US users?

Q4 & Q8 (similarity: 0.782):
X Q4: For point-of-care tests, does the FDA expect the study to be conducted in the US to reflect the US setting?
Q8: What are the FDA's expectations regarding justifications for studies performed outside of the US for home use or point-of-care tests?

Q5 & Q8 (similarity: 0.785):
X Q5: For home use or non-laboratory use tests conducted outside the US, what justification is required to reflect US users?
Q8: What are the FDA's expectations regarding justifications for studies performed outside of the US for home use or point-of-care tests?

Q6 & Q8 (similarity: 0.727):
Q6: What are the FDA requirements for testing instructions for point-of-care tests to ensure they are accessible to US users?
Q8: What are the FDA's expectations regarding justifications for studies performed outside of the US for home use or point-of-care tests?
